var title_f10_9_10384="Adenomatoid malform CT III";
var content_f10_9_10384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation of the left lower lobe in 30-year-old man with recurrent pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays the multicystic nature of the mass-like consolidation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10384=[""].join("\n");
var outline_f10_9_10384=null;
var title_f10_9_10385="Gianotti Crosti";
var content_f10_9_10385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Characteristic rash of Gianotti-Crosti syndrome (papular acrodermatitis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The characteristic rash of Gianotti-Crosti syndrome consists of symmetric pink-brown papular or papulovesicular lesions that are flat-topped and range from 1 to 10 mm in diameter. The face, buttocks, extensor aspects of forearms and legs, and feet are predominantly affected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moise L Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10385=[""].join("\n");
var outline_f10_9_10385=null;
var title_f10_9_10386="Patient information: Pseudogout (The Basics)";
var content_f10_9_10386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/3/11314\">",
"         Patient information: Gout (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/57/24467\">",
"         Patient information: Gout (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/29/21975\">",
"         Patient information: Osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/15/34033\">",
"         Patient information: Pseudogout (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pseudogout (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pseudogout-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1566503\">",
"      <span class=\"h1\">",
"       What is pseudogout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pseudogout is a type of arthritis that causes sudden attacks of joint pain and swelling. It is caused by a build-up of a type of calcium crystals (called &ldquo;calcium pyrophosphate&rdquo;) in the joints.",
"     </p>",
"     <p>",
"      The symptoms of pseudogout are similar to the symptoms of another type of arthritis, called gout. But pseudogout and gout have different causes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566510\">",
"      <span class=\"h1\">",
"       What are the symptoms of pseudogout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with pseudogout get sudden attacks of joint pain, swelling, and warmth&mdash;often in the knee. The symptoms can also happen in the ankles, feet, shoulders, elbows, wrists, and hands. Attacks can last for days or weeks.",
"     </p>",
"     <p>",
"      In some people, pseudogout leads to long-term osteoarthritis. Osteoarthritis is the most common type of arthritis. It causes pain and stiffness in different joints in the body. Sometimes it also causes joint swelling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566517\">",
"      <span class=\"h1\">",
"       Is there a test for pseudogout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check if your symptoms are caused by pseudogout, your doctor will do an exam and tests. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Removing fluid from the painful joint &mdash; A doctor will put a needle in the joint to remove a small sample of fluid. Then he or she will look at the fluid under a microscope to see if the calcium crystals are present.",
"       </li>",
"       <li>",
"        X-rays of the painful joints",
"       </li>",
"       <li>",
"        Blood tests &mdash; Your doctor will do blood tests to see if you have a condition that could be causing the calcium crystals to build up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566524\">",
"      <span class=\"h1\">",
"       How is pseudogout treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment often depends on how many joints are involved.",
"     </p>",
"     <p>",
"      Doctors usually treat people who have 1 or 2 painful joints by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Removing some fluid from the painful joint",
"       </li>",
"       <li>",
"        Giving a shot of a medicine into the painful joint",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors usually treat people who have more than 2 painful joints with medicines called &ldquo;NSAIDs.&rdquo; NSAIDs are a large group of medicines that includes",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=see_link\">",
"       indomethacin",
"      </a>",
"      (sample brand names: Indocin&reg;, Indocid&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;). If people can&rsquo;t take NSAIDs or have too many side effects from NSAIDs, doctors can prescribe other types of medicines.",
"     </p>",
"     <p>",
"      All of these treatments for pseudogout help to shorten an attack and ease joint pain and swelling.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566531\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors usually recommend that people rest their painful joints as much as possible when an attack happens. If your doctor recommends rest, try not to move your painful joint or put weight on it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566538\">",
"      <span class=\"h1\">",
"       Can pseudogout attacks be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. If you get a lot of attacks, your doctor might prescribe a medicine for you to take every day to help prevent future attacks. This medicine is called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"       colchicine",
"      </a>",
"      (brand name: Colcrys&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1566545\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=see_link\">",
"       Patient information: Gout (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"       Patient information: Pseudogout (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"       Patient information: Gout (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       Patient information: Osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/9/10386?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16267 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10386=[""].join("\n");
var outline_f10_9_10386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566503\">",
"      What is pseudogout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566510\">",
"      What are the symptoms of pseudogout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566517\">",
"      Is there a test for pseudogout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566524\">",
"      How is pseudogout treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566531\">",
"      Is there anything I can do on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566538\">",
"      Can pseudogout attacks be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1566545\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=related_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=related_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10387="Gradient echo MRI in CAA";
var content_f10_9_10387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Old hemorrhages on gradient echo MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of CT scan (left), T2- weighted MRI (center), and gradient echo MRI (right) demonstrates the utility of the last for detecting old hemorrhages consistent with cerebral amyloid angiopathy. In addition to the the left frontoparietal hemorrhage seen on all studies (red arrows), the gradient-echo sequence demonstrates multiple areas of decreased signal in gray-white regions (white arrows) consistent with chronic hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996; 46:1751.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10387=[""].join("\n");
var outline_f10_9_10387=null;
var title_f10_9_10388="Flavoxate: Drug information";
var content_f10_9_10388=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flavoxate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/34/14884?source=see_link\">",
"    see \"Flavoxate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flavoxate&reg;;",
"     </li>",
"     <li>",
"      Urispas&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antispasmodic Agent, Urinary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary spasms: Oral: 100-200 mg 3-4 times daily; reduce the dose when symptoms improve.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antispasmodic to provide symptomatic relief of dysuria, nocturia, suprapubic pain, urgency, and incontinence in patients with cystitis, urethritis, urethrocystitis, urethrotrigonitis, and prostatitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FlavoxATE may be confused with fluvoxaMINE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitations, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion (especially in the elderly), drowsiness, headache, hyperpyrexia, nervousness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, intraocular pressure increased, ocular accommodation disorder",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyloric or duodenal obstruction; GI hemorrhage; obstructive intestinal lesions; ileus; achalasia; obstructive uropathies of lower urinary tract (eg, BPH)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause CNS drowsiness and blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with suspected glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Elderly: Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if flavoxate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering flavoxate to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F171429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (FlavoxATE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $146.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor I &amp; O closely",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Baduson (TW);",
"     </li>",
"     <li>",
"      Bladderon (JP);",
"     </li>",
"     <li>",
"      Bladuril (AR, CO, DO, EC, PE);",
"     </li>",
"     <li>",
"      Cleanxate (MY, SG);",
"     </li>",
"     <li>",
"      Flavate (IN);",
"     </li>",
"     <li>",
"      Flavorin (TH);",
"     </li>",
"     <li>",
"      Foxate (TW);",
"     </li>",
"     <li>",
"      Fucotin (TW);",
"     </li>",
"     <li>",
"      Genurin (CL, IT, SG, TW);",
"     </li>",
"     <li>",
"      Genurin S (BR);",
"     </li>",
"     <li>",
"      Harnin (JP);",
"     </li>",
"     <li>",
"      Patricin (JP);",
"     </li>",
"     <li>",
"      Soolda (CL);",
"     </li>",
"     <li>",
"      Spagerin (KP);",
"     </li>",
"     <li>",
"      Spasuret (DE);",
"     </li>",
"     <li>",
"      Spasuri (TH);",
"     </li>",
"     <li>",
"      Tonlin (TW);",
"     </li>",
"     <li>",
"      Uripax (MY, PE);",
"     </li>",
"     <li>",
"      Urispadol (DK);",
"     </li>",
"     <li>",
"      Urispas (200 mg) (NL);",
"     </li>",
"     <li>",
"      Urispas (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CY, EG, ET, FR, GB, GH, GM, GN, HK, IE, IL, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, PT, QA, RU, SA, SC, SD, SG, SL, SN, SY, TN, TR, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Urivox (PK);",
"     </li>",
"     <li>",
"      Uronid (ES);",
"     </li>",
"     <li>",
"      Uropyrine (LU);",
"     </li>",
"     <li>",
"      Uroxal (ID);",
"     </li>",
"     <li>",
"      Uroxate (TH, TW);",
"     </li>",
"     <li>",
"      Verispasmin (GR);",
"     </li>",
"     <li>",
"      Yungken (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic antispasmotic with similar actions to that of propantheline; it exerts a direct relaxant effect on smooth muscles via phosphodiesterase inhibition, providing relief to a variety of smooth muscle spasms; it is especially useful for the treatment of bladder spasticity, whereby it produces an increase in urinary capacity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 55 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (57%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/9/10388/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8448 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10388=[""].join("\n");
var outline_f10_9_10388=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171439\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171472\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171441\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171457\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171442\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881435\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881436\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171423\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171408\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171425\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171476\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171470\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171428\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299338\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171417\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171435\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171418\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171445\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355100\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171429\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171421\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171431\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171411\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171427\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/34/14884?source=related_link\">",
"      Flavoxate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10389="Mexiletine: Drug information";
var content_f10_9_10389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mexiletine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/14/31972?source=see_link\">",
"    see \"Mexiletine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/14/21733?source=see_link\">",
"    see \"Mexiletine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Mexiletine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ib",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Arrhythmias:",
"     </b>",
"     Oral: Initial: 200 mg every 8 hours (may load with 400 mg if necessary); adjust dose every 2-3 days; usual dose: 200-300 mg every 8 hours; maximum: 1.2 g/day (some patients respond to every 12-hour dosing). When switching from another antiarrhythmic, initiate a 200 mg dose 6-12 hours after stopping former agents, 3-6 hours after stopping procainamide.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F196179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with hepatic impairment or CHF may require dose reduction; reduce dose to 25% to 30% of usual dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock rather than 3 times/day to promote less variation in peak and trough serum levels; administer with food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of serious ventricular arrhythmias; suppression of PVCs",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lightheadedness (11% to 25%), dizziness (20% to 25%), nervousness (5% to 10%), incoordination (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI distress (41%), nausea/vomiting (40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Trembling, unsteady gait, tremor (13%), ataxia (10% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3% to 8%), premature ventricular contractions (1% to 2%), palpitation (4% to 8%), angina (2%), proarrhythmia (10% to 15% in patients with malignant arrhythmia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, headache, insomnia (5% to 7%), depression (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation or diarrhea (4% to 5%), xerostomia (3%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%), numbness of fingers or toes (2% to 4%), paresthesia (2%), arthralgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (5% to 7%), nystagmus (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, AV block, cardiogenic shock, CHF, dysphagia, exfoliative dermatitis, hallucinations, hepatic necrosis, hepatitis, hypotension, impotence, leukopenia, myelofibrosis, pancreatitis (rare), psychosis, pulmonary fibrosis, seizure, sinus arrest, SLE syndrome, Stevens-Johnson syndrome, syncope, thrombocytopenia, torsade de pointes, upper GI bleeding, urinary retention, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mexiletine or any component of the formulation; cardiogenic shock; second- or third-degree AV block (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Rare hepatic toxicity may occur; may cause acute hepatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Watch for proarrhythmic effects; monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Use with caution in patients with intraventricular conduction delays, first-degree heart block and/or pre-existing sinus node dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with severe HF; may precipitate or exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with significant hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Use with caution in patients with hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial:",
"     <b>",
"      [U.S. Boxed Warning]: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.",
"     </b>",
"     An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary pH: Alterations in urinary pH may change urinary excretion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Mexiletine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sertraline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Mexiletine may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food may decrease the rate, but not the extent of oral absorption; diets which affect urine pH can increase or decrease excretion of mexiletine. Avoid dietary changes that alter urine pH.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. A few case reports have demonstrated safe use of mexiletine in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13376290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mexiletine concentrations in breast milk are similar to those in the maternal plasma.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9536641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F196160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Mexiletine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $133.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $159.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $184.11",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15577079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F196152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic range: 0.5-2 mcg/mL; potentially toxic: &gt;2 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Meletin (MY);",
"     </li>",
"     <li>",
"      Mexicord (PL);",
"     </li>",
"     <li>",
"      Mexitec (ID);",
"     </li>",
"     <li>",
"      Mexitil (AE, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, GY, HN, HR, HU, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KW, LB, LU, LY, MT, NL, NO, NZ, OM, PT, QA, RU, SA, SE, SK, SR, SY, TR, TT, TW, YE);",
"     </li>",
"     <li>",
"      Mexitilen (AR);",
"     </li>",
"     <li>",
"      Ritalmex (HU);",
"     </li>",
"     <li>",
"      Tumetil (VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class IB antiarrhythmic, structurally related to lidocaine, which inhibits inward sodium current, decreases rate of rise of phase 0, increases effective refractory period/action potential duration ratio",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; elderly have a slightly slower rate, but extent of absorption is the same as young adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5-7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; low first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 10-14 hours (average: elderly: 14.4 hours, younger adults: 12 hours); prolonged with hepatic impairment or heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (10% to 15% as unchanged drug); urinary acidification increases excretion, alkalinization decreases excretion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(12):781-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/9/10389/abstract-text/1900101/pubmed\" id=\"1900101\" target=\"_blank\">",
"        1900101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaker GC, Blackshear JL, McBride R, et al, &ldquo;Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 20:527-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/9/10389/abstract-text/1512329/pubmed\" id=\"1512329\" target=\"_blank\">",
"        1512329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9648 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10389=[""].join("\n");
var outline_f10_9_10389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709085\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196174\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196218\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196177\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196178\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196179\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196151\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196137\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196155\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196154\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196216\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196158\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196141\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196212\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196146\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196169\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206276\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196183\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376290\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9536641\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196160\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15577079\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196152\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038680\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196140\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196157\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9648|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/14/31972?source=related_link\">",
"      Mexiletine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/14/21733?source=related_link\">",
"      Mexiletine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10390="Gastric large cell lymphoma";
var content_f10_9_10390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53702%7EGAST%2F65490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53702%7EGAST%2F65490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Gastric large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastric large cell lymphoma&nbsp;manifested as carcinoma-like ulcerative lesion (large arrow) and several variably sized nodules (small arrows) in adjacent mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal whole mount section on a gastric large cell lymphoma with annular ulcerations and full- thickness infiltration of the gastric wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10390=[""].join("\n");
var outline_f10_9_10390=null;
var title_f10_9_10391="Glyburide and metformin: Drug information";
var content_f10_9_10391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glyburide and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/45/32469?source=see_link\">",
"    see \"Glyburide and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glucovance&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose must be individualized. All doses should be taken with a meal. Twice daily dosage should be taken with the morning and evening meals. Dosages expressed as glyburide/metformin components.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      No prior treatment with sulfonylurea or metformin:",
"     </i>",
"     Initial: 1.25 mg/250 mg once daily with a meal; patients with Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     &gt;9% or fasting plasma glucose (FPG) &gt;200 mg/dL may start with 1.25 mg/250 mg twice daily with meals. Adjustment: Dosage may be increased in increments of 1.25 mg/250 mg, at intervals of not less than 2 weeks; maximum daily dose: 10 mg/2000 mg (limited experience with higher doses);",
"     <b>",
"      Note:",
"     </b>",
"     Doses of 5 mg/500 mg should not be used as initial therapy, due to risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Previously treated with a sulfonylurea or metformin alone:",
"     </i>",
"     Initial: 2.5 mg/500 mg or 5 mg/500 mg twice daily with meals; increase in increments no greater than 5 mg/500 mg; maximum daily dose: 20 mg/2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching patients previously on a sulfonylurea and metformin together, do not exceed the daily dose of glyburide (or glyburide equivalent) or metformin. When adding thiazolidinedione, continue glyburide and metformin at current dose and initiate thiazolidinedione at recommended starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination with thiazolidinedione:",
"     </i>",
"     May be combined with a thiazolidinedione in patients with an inadequate response to glyburide/metformin therapy, however the risk of hypoglycemia may be increased.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Adjust carefully to renal function. Should not be used in patients &ge;80 years of age unless renal function is verified as normal. Do not titrate to maximum dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with serum creatinine &ge;1.5 mg/dL in males, or &ge;1.4 mg/dL in females or abnormal creatinine clearance.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 1.25 mg/250 mg: Glyburide 1.25 mg and metformin hydrochloride 250 mg; 2.5 mg/500 mg: Glyburide 2.5 mg and metformin hydrochloride 500 mg; 5 mg/500 mg: 5 mg/500 mg: Glyburide 5 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Glucovance&reg;: 1.25 mg/250 mg: Glyburide 1.25 mg and metformin hydrochloride 250 mg  [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Glucovance&reg;: 2.5 mg/500 mg: Glyburide 2.5 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Glucovance&reg;: 5 mg/500 mg: Glyburide 5 mg and metformin hydrochloride 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All doses should be administered with a meal. Twice-daily dosing should be administered with the morning and evening meals. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet and exercise for the management of type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Glucovance&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glyburide, metformin, or any component of the formulation; renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females, or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia; acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Temporarily discontinue in patients undergoing radiologic studies in which intravascular iodinated contrast materials are utilized. Temporarily discontinue for surgical procedures.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association. Metformin does not appear to share this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal, hepatic, adrenal and/or pituitary function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially fatal and severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is not specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use metformin with caution in patients with heart failure requiring pharmacologic management, particularly in patients with unstable or acutely decompensated heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thiazolidinediones: Concurrent use with a thiazolidinedione may increase risk of hypoglycemia and/or weight gain. Liver function tests should be monitored periodically with concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Rapid and prolonged hypoglycemia (&gt;12 hours) despite hypertonic glucose injections have been reported; age and hepatic and renal impairment are independent risk factors for hypoglycemia; dosage titration should be made at weekly intervals. Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Metformin therapy should be suspended for any surgical procedures requiring food or fluid restriction (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: GlyBURIDE may enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlyBURIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlyBURIDE. Management: Administer glyburide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May cause hypoglycemia; incidence of lactic acidosis may be increased; a disulfiram-like reaction characterized by flushing, headache, nausea, vomiting, sweating, or tachycardia has been reported with sulfonylureas; avoid or limit use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Metformin decreases absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     . Metformin decreases absorption of folic acid.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted with this combination. Adverse events were not observed in animal studies of the individual agents; therefore, glyburide/metformin is classified as pregnancy category B. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F176788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause GI upset; take with food to decrease GI upset. Dietary modification based on ADA recommendations is a part of therapy. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glucovance Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25-250 mg (100): $123.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-500 mg (100): $146.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $146.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GlyBURIDE-MetFORMIN Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25-250 mg (100): $86.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-500 mg (100): $102.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-500 mg (100): $102.83",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, urine for glucose and ketones, FPG, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , and fructosamine. Initial and periodic monitoring of hematologic parameters (eg, hemoglobin/hematocrit and red blood cell indices) and renal function should be performed; monitor at least annually once patient is on maintenance therapy. While megaloblastic anemia has been rarely seen with metformin, if suspected, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency should be excluded.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AnHe (CL);",
"     </li>",
"     <li>",
"      Bai Kang (CL);",
"     </li>",
"     <li>",
"      Benclamet (IN);",
"     </li>",
"     <li>",
"      Bi-Euglucon (CO, IT, VE);",
"     </li>",
"     <li>",
"      Bi-Euglucon M \"5\" (MX);",
"     </li>",
"     <li>",
"      Bi-Euglucon M (EC, PE, UY);",
"     </li>",
"     <li>",
"      Diamide (MY);",
"     </li>",
"     <li>",
"      Euglo Plus (PH);",
"     </li>",
"     <li>",
"      Glibomet (BG, CR, DO, GT, HN, IT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Gluclean (KP);",
"     </li>",
"     <li>",
"      Glucovance (AU, BB, BE, BG, BR, BS, CH, CN, CO, CZ, EC, FR, HK, ID, JM, KP, MY, NL, PE, PH, PK, PT, RU, SG, TH, TT, TW);",
"     </li>",
"     <li>",
"      Glurid (KP);",
"     </li>",
"     <li>",
"      Glymet (MY);",
"     </li>",
"     <li>",
"      Mydiatab (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The combination of glyburide and metformin is used to improve glycemic control in patients with type 2 diabetes mellitus by using two different, but complementary, mechanisms of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glyburide: Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metformin: Decreases hepatic glucose production, decreasing intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilization)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glucovance&reg;:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bioavailability: 18% with 2.5 mg glyburide/500 mg metformin dose; 7% with 5 mg glyburide/500 mg metformin dose; bioequivalence has not been established between Glucovance&reg; and single ingredient glyburide products; bioavailability was greater than that of a single ingredient brand of glyburide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak: 2.75 hours when taken with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glyburide:",
"     </b>",
"     See Glyburide monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Metformin:",
"     </b>",
"     This component of Glucovance&reg; is bioequivalent to metformin coadministration with glyburide.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/9/10391/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/9/10391/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8748 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10391=[""].join("\n");
var outline_f10_9_10391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708894\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176796\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176813\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176799\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176800\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897365\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897366\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176777\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176762\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176782\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176781\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425702\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176811\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176785\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176766\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299411\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176771\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176794\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176773\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176787\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176803\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176788\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176789\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176786\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176775\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176779\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539872\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176765\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176784\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/45/32469?source=related_link\">",
"      Glyburide and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10392="Apply pin to foreskin1";
var content_f10_9_10392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69386%7EOBGYN%2F77024%7EOBGYN%2F77467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69386%7EOBGYN%2F77024%7EOBGYN%2F77467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Applying safety pin to foreskin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Apply pin to foreskin 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Safety pin on foreskin and Gomco clamp in position prior to excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10392=[""].join("\n");
var outline_f10_9_10392=null;
var title_f10_9_10393="Postnatal care of hydrops fetalis";
var content_f10_9_10393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postnatal care of hydrops fetalis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Michael E Speer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10393/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/9/10393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrops fetalis is a condition of excess fluid accumulation in the fetus that results in significant fetal demise and neonatal mortality. It was first described by Ballantyne in a case series of 65 human fetuses and newborn infants, in which he suggested there were a variety of etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/1\">",
"     1",
"    </a>",
"    ]. In 1943, Potter defined two forms of hydrops fetalis based upon etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune-mediated &mdash; In immune-mediated cases, hydrops fetalis is a result of severe fetal anemia due to destruction of fetal red blood cells by maternal IgG antibodies. Before the introduction of antenatal Rh(D) immune globulin prophylaxis in the 1960s, the most frequent cause of hydrops fetalis was Rh incompatibility between the mother and fetus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"       \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonimmune &mdash; Nonimmune hydrops fetalis (NHF) is associated with numerous disorders that include cardiac, pulmonary, infectious, and genetic etiologies (",
"      <a class=\"graphic graphic_table graphicRef70066 \" href=\"UTD.htm?36/24/37262\">",
"       table 1",
"      </a>",
"      ). NHF accounts for almost 90 percent of current hydropic cases in neonates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The postnatal care of hydrops fetalis will be reviewed here. The antenatal care of Rhesus alloimmunization and nonimmune hydrops fetalis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hydrops fetalis is based upon antenatal ultrasonography that demonstrates two or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin edema",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Pericardial effusion",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Polyhydramnios",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonimmune hydrops fetalis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the implementation of antenatal Rh(D) immune globulin prophylaxis, the incidence of immune-mediated hydrops fetalis has drastically fallen from 80 percent of cases in 1970 to less than 10 percent in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The reported incidence of NHF ranges from 1 in 1500 to 3800 births. The wide variation is based upon differences in population (eg, increased incidence of alpha thalassemia in Southeast Asia) and thoroughness of evaluation, and whether late pregnancy terminations were included in the analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonimmune hydrops fetalis\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review from a large national data set from the United States that identified 598 live-born infants with hydrops fetalis from a cohort of 253,651 infants discharged from a neonatal intensive care unit (NICU), the following were the most common causes of hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital heart problems (14 percent)",
"     </li>",
"     <li>",
"      Heart rate abnormalities (10 percent)",
"     </li>",
"     <li>",
"      Twin to twin transfusions (9 percent)",
"     </li>",
"     <li>",
"      Noncardiac congenital anomalies (9 percent)",
"     </li>",
"     <li>",
"      Chromosomal abnormalities (8 percent)",
"     </li>",
"     <li>",
"      Congenital viral infections (7 percent)",
"     </li>",
"     <li>",
"      Congenital anemia (5 percent)",
"     </li>",
"     <li>",
"      Congenital chylothorax (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an autopsy study of 429 neonates from a tertiary center in the United States, 32 cases (7 percent) had hydrops fetalis, of which 16 infants had cardiovascular disease and 6 had congenital infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Asia, the most common causes of hydrops fetalis are homozygous alpha-thalassemia and cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiologies of nonimmune hydrops fetalis are discussed in greater detail separately (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"UTD.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H8#H8\">",
"     \"Nonimmune hydrops fetalis\", section on 'Disorders associated with hydrops'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the basic mechanisms that underlie the development of hydrops fetalis is important in directing both antenatal and postnatal treatment of hydrops fetalis.",
"   </p>",
"   <p>",
"    Normally, the formation of interstitial fluid from the vascular space is balanced by the return of interstitial fluid back to the central venous system through the lymphatic system. The process is governed by Starling's Law and is dependent upon the four following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capillary hydrostatic pressure",
"     </li>",
"     <li>",
"      Capillary oncotic pressure",
"     </li>",
"     <li>",
"      Interstitial hydrostatic pressure",
"     </li>",
"     <li>",
"      Interstitial osmotic pressure, which is dependent on lymphatic return",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The fetus is particularly vulnerable to increased interstitial fluid accumulation because of its greater capillary permeability, compliant interstitial compartments, and increased susceptibility to impaired lymphatic flow.",
"   </p>",
"   <p>",
"    In cases of hydrops fetalis, accumulation of interstitial fluid occurs because the production of interstitial fluid greatly exceeds the lymphatic return. Although the pathogenesis is not clearly understood, hydrops fetalis appears to be multifactorial due to mechanisms that produce elevated central venous pressure, impair lymphatic return, and increase capillary leakage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elevated venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated central venous pressure (CVP) increases capillary hydrostatic pressure and impairs lymphatic return to the vascular space [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both low (eg, cardiac arrhythmia, congenital structural heart disease, and myocarditis) and high-output cardiac failure (eg, severe anemia, arterial-venous malformations, and twin-twin transfusion syndrome) cause elevated CVP that may result in hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,11-19\">",
"     4,11-19",
"    </a>",
"    ]. Elevation of CVP appears to be a critical component in the pathogenesis of hydrops fetalis because animal studies have demonstrated that severe anemia alone does not cause hydrops fetalis but only in the presence of increased CVP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CVP elevation may also be caused by obstruction of either the superior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inferior vena cavas as demonstrated in cases of congenital cystic adenomatoid malformation, omphalocele, cervical or mediastinal teratoma, or congenital high airway obstruction syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Compression of the vascular system impedes lymphatic return and results in edema formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Impaired lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph return to the central venous system is reduced either by structural abnormality or, as previously discussed, functional impairment due to increased central venous pressure.",
"   </p>",
"   <p>",
"    Anomalous development results in structural dysgenesis of the lymphatic network and is seen in the following conditions; chylothorax, cervical hygroma, congenital lymphedema, and cystic lymphangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,27-30\">",
"     4,27-30",
"    </a>",
"    ]. These structural anomalies are often associated with chromosomal abnormalities, such as Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Capillary oncotic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, reduced capillary oncotic pressure should contribute to hydrops fetalis. However, data from animal studies demonstrated that hypoproteinemia does not result in NHF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies have shown that severe fetal hypoxia causes hydrops fetalis. In these studies, there is sustained activation of the renin-angiotensin system with elevation of renin in the absence of renal injury or elevation of central venous pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In addition, hypoxia results in endothelial injury and interferes with nitric oxide and cyclic guanosine monophosphate production [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], which may increase capillary leakage resulting in greater movement of fluid from the vascular to the interstitial space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, most cases of hydrops fetalis will be diagnosed prior to delivery because of the routine use of antenatal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/37\">",
"     37",
"    </a>",
"    ]. Antenatal evaluation and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The delivery of a fetus with hydrops fetalis requires close collaboration between the perinatologist and neonatologist. The care of a known affected case should take place at a tertiary center that can offer intrauterine intervention including prenatal exchange transfusion, expertise in neonatal resuscitation and pediatric surgery, and postnatal mechanical ventilatory support and exchange transfusion.",
"   </p>",
"   <p>",
"    Postnatal management is divided into initial resuscitation directed towards stabilizing the cardiopulmonary status in the delivery room, assessment to identify the underlying cause, and if possible, directed therapy focused upon treating the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of delivery, hydrops fetalis increases the risk of birth trauma due to soft tissue dystocia, postpartum hemorrhage, and retained placenta. In utero aspiration of the pleural fluid or ascites prior to delivery may reduce the risk of dystocia and facilitate neonatal resuscitation. Cesarean birth should be reserved for routine obstetrical indications; however, the high frequency of nonreassuring fetal heart rate patterns and dystocia associated with hydrops fetalis increases the likelihood of cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H26#H26\">",
"     \"Nonimmune hydrops fetalis\", section on 'Prognosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although prenatal ultrasound should provide guidance upon the level of resuscitation required, delivery room management should anticipate the needs of the most severely affected infant. Preparation should anticipate the need to drain fluid if significant ascites. Pleural effusions or pericardial effusions compromise ventilation or cardiac output, especially if the fluid has not been drained prior to delivery. If severe anemia is anticipated, unmatched type O, Rh- negative packed red blood cells should be available.",
"   </p>",
"   <p>",
"    For initial neonatal resuscitation, we suggest using the guidelines jointly developed by the American Heart Association, American Academy of Pediatrics, and International Liaison Committee on Resuscitation that focus on the following three steps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial steps (provide warmth, position head, clear",
"      <strong>",
"       A",
"      </strong>",
"      irway, dry, and stimulate)",
"     </li>",
"     <li>",
"      Breathing (ventilation)",
"     </li>",
"     <li>",
"      Circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most affected infants require endotracheal intubation because of respiratory depression. Intubation may be difficult because of edema of the head, neck, and oropharynx, thus, the most experienced available clinician should perform the procedure.",
"   </p>",
"   <p>",
"    Drainage of pleural effusions and ascites by needle aspiration may be necessary, if adequate ventilation is not achieved after intubation. Paracentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracentesis are performed using an 18- to 20-gauge angiocatheter attached to a three-way stopcock and syringe. After entry into the chest or abdominal cavity, the needle is removed and the plastic catheter remains in place to prevent damage to either the underlying lung or abdominal organs. Fluid is gently aspirated by syringe. In some cases, cardiocentesis may be required if there is evidence of cardiac tamponade.",
"   </p>",
"   <p>",
"    Hydropic infants frequently require mechanical ventilatory support, even following drainage, as many will have pulmonary hypoplasia or respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the infant is born at or before 30 weeks gestation, prophylactic surfactant therapy is given. In older infants, rescue surfactant is considered if the arterial to alveolar oxygen ratio is less than 0.22 to 0.3. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pallor, tachycardia, and tachypnea are findings suggestive of either cardiogenic shock or severe symptomatic anemia. Central venous lines are necessary for monitoring pressures and obtaining blood for testing, and if necessary, administration of fluids and medications, and for partial exchange transfusion. Catheterization of the umbilical vein provides quick central venous access.",
"   </p>",
"   <p>",
"    Although most hydropic infants are normovolemic, fluid resuscitation may be required in infants near cardiovascular collapse. Inotropic support (eg, dopamine) may be required to improve cardiac output, especially in infants with low-output cardiac failure.",
"   </p>",
"   <p>",
"    If known or suspected fetal anemia is suspected as the underlying cause of hydrops fetalis, a simple careful transfusion or an isovolemic partial exchange transfusion with packed group O, Rh(D) negative red blood cells should be performed. Isovolemic exchange is preferred as these infants will have normal or increased vascular volume, and elevated central venous pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the cardiopulmonary systems are stabilized, diagnostic evaluation is performed to determine the underlying cause of hydrops fetalis. Determining the etiology of the hydrops fetalis may direct further evaluation, guide treatment, and provide information for both the prognosis of the affected infant and genetic counseling for future pregnancies.",
"   </p>",
"   <p>",
"    Assessment includes examination of the infant and the placenta, and diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Examination of the infant and placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment begins with examination of the infant and the placenta.",
"   </p>",
"   <p>",
"    Neonatal physical findings that are useful in directing the evaluation and management of the affected child include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent cyanosis that is unresponsive to oxygen suggests the presence of structural heart disease or cardiac myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/14-17,39,40\">",
"       14-17,39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of dermal hematopoiesis and hepatomegaly, with or without splenomegaly, is suggestive of intrauterine congenital viral infections (eg, cytomegalovirus and rubella) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link\">",
"       \"Overview of TORCH infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotonia may be seen in hydropic infants with congenital myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/43-45\">",
"       43-45",
"      </a>",
"      ] or inherited error of metabolism including storage diseases, such as Gaucher disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. In addition, cases of congenital hypothyroidism, which is associated with hypotonia, have been reported in hydropic infants [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"       \"Congenital myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"       \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to hypotonia, other clinical features of metabolic storage diseases may include hepatomegaly, facial dysmorphism, and cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/51-55\">",
"       51-55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings suggestive of a chromosomal abnormality may be present, such as congenital lymphedema of the hands and feet, webbed neck, nail dysplasia, high palate, and short fourth metacarpal seen in infants with Turner syndrome. Other chromosomal abnormalities associated with hydrops fetalis include Trisomies 21, 18, and 12; and triploidy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"       \"Congenital cytogenetic abnormalities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other anomalies associated with hydrops fetalis, such as omphalocele and intrathoracic masses, may be detected on physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The placenta should be examined for evidence of chorioangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/56\">",
"     56",
"    </a>",
"    ], congenital infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/57\">",
"     57",
"    </a>",
"    ], and in the case of twin pregnancies, twin-to-twin transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies include blood gas measurements, complete blood count, and if anemia is suspected, type and cross match.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood gas measurements provide information on the infant's cardiopulmonary status and guides further interventions.",
"     </li>",
"     <li>",
"      Complete blood count includes the hematocrit, which can assess whether anemia is present, and if so, the severity of anemia. Examination of the blood smear can determine whether there is an ongoing hemolytic process and may provide clues to the diagnosis of the underlying cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further diagnostic studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac evaluation &mdash; In infants suspected to have cardiac abnormalities (",
"      <a class=\"graphic graphic_table graphicRef77350 \" href=\"UTD.htm?16/5/16475\">",
"       table 2",
"      </a>",
"      ), we perform an electrocardiogram to detect arrhythmias and echocardiogram to detect cardiac structural and functional abnormalities in all hydropic infants.",
"     </li>",
"     <li>",
"      Thoracic and abdominal evaluation &mdash; Radiographs are useful to ascertain the presence and size of pleural effusions, and as a screen for potential mass lesions, and pulmonary or cardiac disease. If there is a suspicion for an intrathoracic or abdominal abnormality, other imaging modalities, such as computerized tomography, ultrasonography, or magnetic resonance imaging provide better resolution to identify the abnormality (eg, cystic adenomatoid malformation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,25\">",
"       4,25",
"      </a>",
"      ], leiomyosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/23\">",
"       23",
"      </a>",
"      ], or pulmonary sequestration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/58\">",
"       58",
"      </a>",
"      ]) (",
"      <a class=\"graphic graphic_table graphicRef66844 \" href=\"UTD.htm?1/48/1803\">",
"       table 3",
"      </a>",
"      ). Identification of surgically correctable lesions is important as there are case reports of improved outcome with surgical intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/23,59\">",
"       23,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evaluation for infection &mdash; Both congenital bacterial and viral infections are associated with cases of hydrops fetalis (",
"      <a class=\"graphic graphic_table graphicRef72575 \" href=\"UTD.htm?11/19/11580\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,60\">",
"       4,60",
"      </a>",
"      ]. Intrauterine infection of the fetus may arise from pathogens that ascend from the vagina and cervix, or are transferred from the maternal circulation through the uteroplacental circulation. Individual infections have characteristic histopathologic findings within the placenta. Thus, placental examination by a pathologist should be performed when infection is considered as a causal or contributing factor for hydrops fetalis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link\">",
"       \"Placental infections\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Congenital viral infections are the most common infectious agents associated with hydrops fetalis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4\">",
"       4",
"      </a>",
"      ]. Currently, diagnostic testing for congenital viral infections includes serologic testing and cultures of different body fluids depending upon the organism. However, both serologic testing and viral cultures have limitations in their ability to accurately diagnosis congenital viral infections. In the future, tests based upon molecular techniques, such as polymerase chain reaction, will likely replace viral cultures and serologic assessment in the diagnosis of congenital viral infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H609355024#H609355024\">",
"       \"Overview of TORCH infections\", section on 'Approach to the infant with suspected intrauterine infection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hydrops fetalis associated with cytomegalovirus (CMV) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,5\">",
"       4,5",
"      </a>",
"      ], parvovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,5\">",
"       4,5",
"      </a>",
"      ], syphilis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/57,61,62\">",
"       57,61,62",
"      </a>",
"      ], and toxoplasmosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/63\">",
"       63",
"      </a>",
"      ], is generally due to anemia and the resultant high-output cardiac failure. There are also cases of hydrops fetalis due to myocarditis from CMV [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/64\">",
"       64",
"      </a>",
"      ], parvovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/5\">",
"       5",
"      </a>",
"      ], and coxsackie virus [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evaluation of anemia &mdash; As discussed previously, prompt intervention with transfusion should be performed in infants with severe symptomatic anemia. Once the cardiopulmonary status of the infant is stabilized, the cause of anemia should be determined or confirmed if there was a predetermined antenatal cause. Anemia can be due to hemolysis, such as isoimmune hemolytic anemia or inherited disorders of red blood cells (eg, homozygous alpha thalassemia or hereditary spherocytosis), blood loss from fetal to maternal hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/66,67\">",
"       66,67",
"      </a>",
"      ], or reduced fetal red blood cell production (eg, parvovirus B12 infection) (",
"      <a class=\"graphic graphic_table graphicRef62279 \" href=\"UTD.htm?38/36/39499\">",
"       table 5",
"      </a>",
"      ). An unusual form of anemia (transient abnormal myelopoiesis or transient leukemia) is found in 10 percent of newborn infants with Trisomy 21. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link&amp;anchor=H25#H25\">",
"       \"Pathophysiology of alpha thalassemia\", section on 'Hydrops fetalis and hemoglobin Bart's'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"       \"Overview of hemolytic anemias in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features and diagnosis of Down syndrome\", section on 'Transient leukemia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Examination of the blood smear will determine whether hemolysis is the cause of anemia. If hemolysis is present, further testing includes the infant's blood type, Coombs test, and tests to identify inherited red blood cell disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link\">",
"       \"Overview of hemolytic anemias in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If fetal maternal hemorrhage is suspected, Kleihauer-Betke test, which measures the percentage of fetal red blood in the maternal blood by flow cytometry, can be used to support the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link&amp;anchor=H11#H11\">",
"       \"Prevention of Rh(D) alloimmunization\", section on 'Testing for fetomaternal hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Karyotyping &mdash; Karyotyping should be performed prenatally if possible through amniocentesis, chorionic villus, or fetal blood sampling. Antenatal karyotyping is useful information when reviewing antenatal management options with the parents, such as termination of the pregnancy or invasive therapeutic interventions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H25#H25\">",
"       \"Nonimmune hydrops fetalis\", section on 'Evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If fetal karyotyping has not been performed, then karyotyping should be performed regardless of the outcome of the infant because hydrops fetalis is associated with an increased risk of a chromosomal abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/68-70\">",
"       68-70",
"      </a>",
"      ]. Genetic counseling should be provided to parents if a chromosomal abnormality is detected to direct the management of future pregnancies.",
"     </li>",
"     <li>",
"      Evaluation for inborn errors of metabolic disease &mdash; Metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite (",
"      <a class=\"graphic graphic_table graphicRef57407 \" href=\"UTD.htm?24/50/25387\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/51-55,71-73\">",
"       51-55,71-73",
"      </a>",
"      ]. The outcome for",
"      <span class=\"nowrap\">",
"       infants/fetuses",
"      </span>",
"      with hydrops fetalis and an inborn error of metabolic disease is poor. In addition, the recurrence rate for future pregnancies is high as most of these diseases are due to an inherited genetic defect. As a result, the diagnosis is important for future family planning [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/74\">",
"       74",
"      </a>",
"      ]. The evaluation of inborn errors of metabolism is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare causes &mdash; A rare inheritable condition to consider is familial hemophagocytic lymphohistiocytosis due to mutation in the gene that encodes for Munc13-4 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Further management",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, mechanical ventilation is often required because of lung hypoplasia. In addition, continued drainage of persistent pleural effusions and ascites may be needed.",
"   </p>",
"   <p>",
"    Additional management is directed towards the underlying cause of hydrops fetalis and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correction of anemia and treatment of hyperbilirubinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link\">",
"       \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Correction of cardiac arrhythmias with cardioversion, medication, or pacing",
"     </li>",
"     <li>",
"      Surgical excision of resectable masses [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Administration of appropriate antimicrobial agents in infants with infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite intensive prenatal and postnatal interventions, live-born infants with hydrops fetalis have a 50 percent mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4,6,37,76-78\">",
"     4,6,37,76-78",
"    </a>",
"    ]. Mortality rate is dependent upon the underlying cause of hydrops fetalis.",
"   </p>",
"   <p>",
"    In the previously mentioned review of 598 live-born infants with hydrops fetalis, the mortality rate was highest in infants with congenital anomalies (58 percent) and lowest in infants with isolated congenital chylothorax (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/4\">",
"     4",
"    </a>",
"    ]. In a logistic regression analyses, risk factors associated with decreased survival included lower gestational age, five minute Apgar score of 3 or less, and need for greater supportive care defined by high concentration of inspired oxygen and high-frequency ventilatory support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neurodevelopment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In survivors of hydrops fetalis, poor neurodevelopment outcome appears to be the most significant morbidity. This was illustrated in the following case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case series, 19 of 51 live-born infants with hydrops fetalis survived beyond one year of life [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/79\">",
"       79",
"      </a>",
"      ]. At one year follow-up, thirteen patients had normal development, two had mild developmental delay, one had intellectual disability (mental retardation), and three had severe psychomotor retardation, of which two of the three patients were very low birth weight infants (birth weight less than 1500 g).",
"     </li>",
"     <li>",
"      In a retrospective study of 11 infants with hydrops fetalis due to fetal tachycardia, of which 10 received intrauterine treatment, neonatal cranial ultrasonography demonstrated periventricular echogenicity in three patients (including one patient with a pseudocyst), and porencephalic cyst suggestive of an antenatal parenchymal hemorrhage in another patient [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/80\">",
"       80",
"      </a>",
"      ]. The other seven infants had normal studies. Ten patients were discharged from the NICU and were assessed for cognitive and neurologic function between 6 months and 12 years of age. Eight patients had normal neurologic and cognitive function, and one patient had mild hemiplegia with normal cognitive ability, and one had cognitive developmental delay.",
"     </li>",
"     <li>",
"      Prognosis is generally poor in patients with twin-twin transfusion because they are frequently delivered prior to 30 weeks gestation. In one case series of 25 pregnancies with twin-twin transfusion, hydrops fetalis presented in 10 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/19\">",
"       19",
"      </a>",
"      ]. Two-thirds of hydropic infants died and, of the survivors, half had cerebral palsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the findings in these studies, neurodevelopmental evaluation should be provided to all survivors of hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10393/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrence depends upon the underlying etiology. The recurrence rate is greatest in families with infants who have a chromosomal abnormality. &nbsp;Therefore, every effort should be made to determine the cause of hydrops including autopsies and karyotyping of non-surviving infants and non-viable fetuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrops fetalis is defined as the presence of two or more of the following fetal findings (eg, skin edema, pleural effusion, pericardial effusion, ascites, polyhydramnios). It may be caused by immune or nonimmune mediated processes.",
"     </li>",
"     <li>",
"      With the widespread use of antenatal Rh(D) immune globulin prophylaxis, nonimmune causes account for 90 percent of the cases of hydrops fetalis. The causes of nonimmune hydrops fetalis are heterogeneous and include cardiac, pulmonary, metabolic, hematologic, and infectious etiologies (",
"      <a class=\"graphic graphic_table graphicRef70066 \" href=\"UTD.htm?36/24/37262\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H8#H8\">",
"       \"Nonimmune hydrops fetalis\", section on 'Disorders associated with hydrops'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the pathogenesis is not clearly understood, hydrops fetalis appears to be multifactorial due to mechanisms that produce elevated central venous pressure, impair lymphatic return, and increase capillary leakage. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In developed countries, with the routine use of antenatal ultrasound, most cases of hydrops fetalis will be diagnosed prior to delivery. Intrauterine evaluation and management provided at a tertiary center may improve perinatal outcome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"       \"Nonimmune hydrops fetalis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The delivery of a fetus with hydrops fetalis requires close collaboration between the perinatologist and neonatologist. We suggest that delivery should be at a tertiary center with expertise in neonatal resuscitation, pediatric surgery, exchange transfusion, and mechanical ventilation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Postnatal management is divided into initial resuscitation, assessment to identify the underlying cause, and treatment of the underlying cause, if possible. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial resuscitation is directed towards stabilizing the cardiopulmonary status of the infant. We suggest following guidelines jointly developed by the American Heart Association, American Academy of Pediatrics, and International Liaison Committee on Resuscitation for initial neonatal resuscitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"       \"Neonatal resuscitation in the delivery room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition, delivery room management includes preparation to drain fluid if significant ascites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusions compromise ventilation and the availability of unmatched type O, Rh- negative packed red blood cells for transfusion in cases of severe anemia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the cardiopulmonary system of the infant is stabilized, diagnostic evaluation is performed to determine the underlying cause of hydrops fetalis. Determining the etiology of the hydrops fetalis may direct further evaluation, guide treatment, and provide information on prognosis of the affected infant and genetic counseling for future pregnancies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Further management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality rate for live-born infants with hydrops fetalis is approximately 50 percent and varies dependent upon the underlying cause of hydrops fetalis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ballantyne JW. The diseases and deformities of the foetus: An attempt towards a new system of ante-natal pathology. Edinburgh, Oliver &amp; Boyd, 1892.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/2\">",
"      Potter EL. Universal edema of the fetus unassociated with erythroblastosis. Am J Obstet Gynecol 1943; 46:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/3\">",
"      Macafee CA, Fortune DW, Beischer NA. Non-immunological hydrops fetalis. J Obstet Gynaecol Br Commonw 1970; 77:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/4\">",
"      Abrams ME, Meredith KS, Kinnard P, Clark RH. Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics 2007; 120:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/5\">",
"      Rodr&iacute;guez MM, Bruce JH, Jim&eacute;nez XF, et al. Nonimmune hydrops fetalis in the liveborn: series of 32 autopsies. Pediatr Dev Pathol 2005; 8:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/6\">",
"      Yang YH, Teng RJ, Tang JR, et al. Etiology and outcome of hydrops fetalis. J Formos Med Assoc 1998; 97:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/7\">",
"      Liao C, Wei J, Li Q, et al. Nonimmune hydrops fetalis diagnosed during the second half of pregnancy in Southern China. Fetal Diagn Ther 2007; 22:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/8\">",
"      Huang HR, Tsay PK, Chiang MC, et al. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. Am J Perinatol 2007; 24:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/9\">",
"      Gest AL, Bair DK, Vander Straten MC. The effect of outflow pressure upon thoracic duct lymph flow rate in fetal sheep. Pediatr Res 1992; 32:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/10\">",
"      Gest AL, Bair DK, Vander Straten MC. Thoracic duct lymph flow in fetal sheep with increased venous pressure from electrically induced tachycardia. Biol Neonate 1993; 64:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/11\">",
"      Kanzaki T, Chiba Y. Evaluation of the preload condition of the fetus by inferior vena caval blood flow pattern. Fetal Diagn Ther 1990; 5:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/12\">",
"      Weiner CP. Umbilical pressure measurement in the evaluation of nonimmune hydrops fetalis. Am J Obstet Gynecol 1993; 168:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/13\">",
"      Chiba Y, Kobayashi H, Kanzaki T, Murakami M. Quantitative analysis of cardiac function in non-immunological hydrops fetalis. Fetal Diagn Ther 1990; 5:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/14\">",
"      Knilans TK. Cardiac abnormalities associated with hydrops fetalis. Semin Perinatol 1995; 19:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/15\">",
"      Henrich W, Fuchs I, B&uuml;hrer C, et al. Isolated cardiomegaly in the second trimester as an early sign of fetal hydrops due to intracranial arteriovenous malformation. J Clin Ultrasound 2003; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/16\">",
"      Jaeggi ET, Hornberger LK, Smallhorn JF, Fouron JC. Prenatal diagnosis of complete atrioventricular block associated with structural heart disease: combined experience of two tertiary care centers and review of the literature. Ultrasound Obstet Gynecol 2005; 26:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/17\">",
"      Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart 1998; 79:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/18\">",
"      Hayakawa M, Oshiro M, Mimura S, et al. Twin-to-twin transfusion syndrome with hydrops: a retrospective analysis of ten cases. Am J Perinatol 1999; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/19\">",
"      Matsuda Y, Kouno S. Fetal and neonatal outcomes in twin oligohydramnios-polyhydramnios sequence including cerebral palsy. Fetal Diagn Ther 2002; 17:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/20\">",
"      Blair DK, Vander Straten MC, Gest AL. Hydrops in fetal sheep from rapid induction of anemia. Pediatr Res 1994; 35:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/21\">",
"      Moise KJ Jr, Carpenter RJ Jr, Hesketh DE. Do abnormal Starling forces cause fetal hydrops in red blood cell alloimmunization? Am J Obstet Gynecol 1992; 167:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/22\">",
"      Ierullo AM, Ganapathy R, Crowley S, et al. Neonatal outcome of antenatally diagnosed congenital cystic adenomatoid malformations. Ultrasound Obstet Gynecol 2005; 26:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/23\">",
"      Golladay ES, Mollitt DL. Surgically correctable fetal hydrops. J Pediatr Surg 1984; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/24\">",
"      Lim FY, Crombleholme TM, Hedrick HL, et al. Congenital high airway obstruction syndrome: natural history and management. J Pediatr Surg 2003; 38:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/25\">",
"      Rice HE, Estes JM, Hedrick MH, et al. Congenital cystic adenomatoid malformation: a sheep model of fetal hydrops. J Pediatr Surg 1994; 29:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/26\">",
"      Wesolowski A, Piazza A. A case of mediastinal teratoma as a cause of nonimmune hydrops fetalis, and literature review. Am J Perinatol 2008; 25:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/27\">",
"      Tanriverdi HA, Ertan AK, Hendrik HJ, et al. Outcome of cystic hygroma in fetuses with normal karyotypes depends on associated findings. Eur J Obstet Gynecol Reprod Biol 2005; 118:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/28\">",
"      Bellini C, Mazzella M, Arioni C, et al. Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia. Am J Med Genet A 2003; 120A:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/29\">",
"      Daniel-Spiegel E, Ghalamkarpour A, Spiegel R, et al. Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 2005; 25:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/30\">",
"      Bellini C, Hennekam RC, Boccardo F, et al. Nonimmune idiopathic hydrops fetalis and congenital lymphatic dysplasia. Am J Med Genet A 2006; 140:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/31\">",
"      Basgul A, G&uuml;d&uuml;c&uuml; N, Kavak ZN, et al. Three fetuses karyotyped as Turner syndrome with cystic hygroma developing hydrops: prognosis and outcome. Clin Exp Obstet Gynecol 2007; 34:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/32\">",
"      Mo&iuml;se AA, Gest AL, Weickmann PH, McMicken HW. Reduction in plasma protein does not affect body water content in fetal sheep. Pediatr Res 1991; 29:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/33\">",
"      O'Connell AE, Boyce AC, Lumbers ER, Gibson KJ. The effects of asphyxia on renal function in fetal sheep at midgestation. J Physiol 2003; 552:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/34\">",
"      Lumbers ER, Gunn AJ, Zhang DY, et al. Nonimmune hydrops fetalis and activation of the renin-angiotensin system after asphyxia in preterm fetal sheep. Am J Physiol Regul Integr Comp Physiol 2001; 280:R1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/35\">",
"      De Groot CJ, Oepkes D, Egberts J, Kanhai HH. Evidence of endothelium involvement in the pathophysiology of hydrops fetalis? Early Hum Dev 2000; 57:205.",
"     </a>",
"    </li>",
"    <li>",
"     Gidday JM, Park TS, Shah AR, Gonzales ER. Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide. Stroke 1998; 29:1423; discussion 1429-30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/37\">",
"      Wafelman LS, Pollock BH, Kreutzer J, et al. Nonimmune hydrops fetalis: fetal and neonatal outcome during 1983-1992. Biol Neonate 1999; 75:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/38\">",
"      Phibbs RH, Johnson P, Tooley WH. Cardiorespiratory status of erythroblastotic newborn infants. II. Blood volume, hematocrit, and serum albumin concentration in relation to hydrops fetalis. Pediatrics 1974; 53:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/39\">",
"      Kothari DS, Skinner JR. Neonatal tachycardias: an update. Arch Dis Child Fetal Neonatal Ed 2006; 91:F136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/40\">",
"      Tanel RE, Rhodes LA. Fetal and neonatal arrhythmias. Clin Perinatol 2001; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     Rudolph AJ. Atlas of the Newborn. Vol. 5. Thorax, Abdomen, Blood, Endocrine and Metabolic Disorders. BC Decker Inc, Hamilton, Canada 1997. p. 197.",
"    </li>",
"    <li>",
"     Rudolph AJ. Atlas of the Newborn. Vol. 4. Dermatology and Perinatal Infection. BC Decker Inc, Hamilton, Canada 1997. p.118,127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/43\">",
"      Afifi AM, Bhatia AR, Eyal F. Hydrops fetalis associated with congenital myotonic dystrophy. Am J Obstet Gynecol 1992; 166:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/44\">",
"      Dufour P, Berard J, Vinatier D, et al. Myotonic dystrophy and pregnancy. A report of two cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 1997; 72:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/45\">",
"      Vardon D, Chau C, Sigodi S, et al. Congenital rapidly fatal form of nemaline myopathy with fetal hydrops and arthrogryposis. A case report and review. Fetal Diagn Ther 1998; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/46\">",
"      Steenhout P, Elmer C, Clercx A, et al. Carnitine deficiency with cardiomyopathy presenting as neonatal hydrops: successful response to carnitine therapy. J Inherit Metab Dis 1990; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/47\">",
"      Lazebnik N, Lazebnik RS. The prenatal presentation of congenital erythropoietic porphyria: report of two siblings with elevated maternal serum alpha-fetoprotein. Prenat Diagn 2004; 24:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/48\">",
"      Kassem E, Dolfin T, Litmanowitz I, et al. Familial perinatal hemochromatosis: a disease that causes recurrent non-immune hydrops. J Perinat Med 1999; 27:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/49\">",
"      Watson WJ, Fiegen MM. Fetal thyrotoxicosis associated with nonimmune hydrops. Am J Obstet Gynecol 1995; 172:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/50\">",
"      Kessel I, Makhoul IR, Sujov P. Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Pediatrics 1999; 103:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/51\">",
"      Lemyre E, Russo P, Melan&ccedil;on SB, et al. Clinical spectrum of infantile free sialic acid storage disease. Am J Med Genet 1999; 82:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/52\">",
"      Mignot C, Gelot A, Bessi&egrave;res B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A 2003; 120A:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/53\">",
"      Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/54\">",
"      Pattison S, Pankarican M, Rupar CA, et al. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Hum Mutat 2004; 23:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/55\">",
"      Staretz-Chacham O, Lang TC, LaMarca ME, et al. Lysosomal storage disorders in the newborn. Pediatrics 2009; 123:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/56\">",
"      Russell RT, Carlin A, Ashworth M, Welch CR. Diffuse placental chorioangiomatosis and fetal hydrops. Fetal Diagn Ther 2007; 22:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/57\">",
"      Barton JR, Thorpe EM Jr, Shaver DC, et al. Nonimmune hydrops fetalis associated with maternal infection with syphilis. Am J Obstet Gynecol 1992; 167:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/58\">",
"      da Silva OP, Ramanan R, Romano W, et al. Nonimmune hydrops fetalis, pulmonary sequestration, and favorable neonatal outcome. Obstet Gynecol 1996; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/59\">",
"      Mitanchez D, Gr&eacute;bille AG, Parat S, et al. Delayed surgery in pericardial teratoma with neonatal hydrops. Eur J Pediatr Surg 2005; 15:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/60\">",
"      Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol 1995; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/61\">",
"      Berkowitz K, Baxi L, Fox HE. False-negative syphilis screening: the prozone phenomenon, nonimmune hydrops, and diagnosis of syphilis during pregnancy. Am J Obstet Gynecol 1990; 163:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/62\">",
"      Chawla V, Pandit PB, Nkrumah FK. Congenital syphilis in the newborn. Arch Dis Child 1988; 63:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/63\">",
"      Zornes SL, Anderson PG, Lott RL. Congenital toxoplasmosis in an infant with hydrops fetalis. South Med J 1988; 81:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/64\">",
"      Sampath V, Narendran V, Donovan EF, et al. Nonimmune hydrops fetalis and fulminant fatal disease due to congenital cytomegalovirus infection in a premature infant. J Perinatol 2005; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/65\">",
"      Bates HR Jr. Coxsackie virus B3 calcific pancarditis and hydrops fetalis. Am J Obstet Gynecol 1970; 106:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/66\">",
"      Lau MS, Tan JV, Tan TY, et al. Idiopathic chronic fetomaternal haemorrhage resulting in hydrops--a case report. Ann Acad Med Singapore 2003; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/67\">",
"      Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/68\">",
"      Allan LD, Sharland GK, Chita SK, et al. Chromosomal anomalies in fetal congenital heart disease. Ultrasound Obstet Gynecol 1991; 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/69\">",
"      Nadel A, Bromley B, Benacerraf BR. Nuchal thickening or cystic hygromas in first- and early second-trimester fetuses: prognosis and outcome. Obstet Gynecol 1993; 82:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/70\">",
"      Landrum BG, Johnson DE, Ferrara B, et al. Hydrops fetalis and chromosomal trisomies. Am J Obstet Gynecol 1986; 154:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/71\">",
"      Claeys M, Van der Hoeven M, de Die-Smulders C, et al. Early-infantile type of galactosialidosis as a cause of heart failure and neonatal ascites. J Inherit Metab Dis 1999; 22:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/72\">",
"      Chab&aacute;s A, Gort L, D&iacute;az-Font A, et al. Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease. Blood Cells Mol Dis 2005; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/73\">",
"      Colmant C, Picone O, Froissart R, et al. Second-trimester diagnosis of mucopolysaccharidosis type IV a presenting as hydrops fetalis. Prenat Diagn 2006; 26:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/74\">",
"      Haverkamp F, Jacobs D, Cantz M, et al. Nonimmune hydrops fetalis with galactosialidosis: consequences for family planning. Fetal Diagn Ther 1996; 11:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/75\">",
"      Bechara E, Dijoud F, de Saint Basile G, et al. Hemophagocytic lymphohistiocytosis with Munc13-4 mutation: a cause of recurrent fatal hydrops fetalis. Pediatrics 2011; 128:e251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/76\">",
"      Wy CA, Sajous CH, Loberiza F, Weiss MG. Outcome of infants with a diagnosis of hydrops fetalis in the 1990s. Am J Perinatol 1999; 16:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/77\">",
"      Mascaretti RS, Falc&atilde;o MC, Silva AM, et al. Characterization of newborns with nonimmune hydrops fetalis admitted to a neonatal intensive care unit. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/78\">",
"      Rose CH, Bofill JA, Le M, Martin RW. Non-immune hydrops fetalis: prenatal diagnosis and perinatal outcomes. J Miss State Med Assoc 2005; 46:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/79\">",
"      Nakayama H, Kukita J, Hikino S, et al. Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis. Acta Paediatr 1999; 88:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10393/abstract/80\">",
"      Oudijk MA, Gooskens RH, Stoutenbeek P, et al. Neurological outcome of children who were treated for fetal tachycardia complicated by hydrops. Ultrasound Obstet Gynecol 2004; 24:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5027 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10393=[""].join("\n");
var outline_f10_9_10393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elevated venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Impaired lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Capillary oncotic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypoxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Examination of the infant and placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Further management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neurodevelopment outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/24/37262\" title=\"table 1\">",
"      Causes nonimmune hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/5/16475\" title=\"table 2\">",
"      Cardiac defects causing hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/48/1803\" title=\"table 3\">",
"      Thoracic defects causing hydrop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/19/11580\" title=\"table 4\">",
"      Infections causes of hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/36/39499\" title=\"table 5\">",
"      Hematologic causes of NHF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/50/25387\" title=\"table 6\">",
"      Metabolic causes hydrops",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=related_link\">",
"      First trimester cystic hygroma and increased nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10394="Perioperative care of the surgical patient with neurologic disease";
var content_f10_9_10394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative care of the surgical patient with neurologic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Geno J Merli, MD, FACP, FHM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Rodney D Bell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/9/10394/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/9/10394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative care of the patient with neurologic disease is a challenge for the medical consultant. The most important considerations are the management of medications used to treat neurologic disorders, an understanding of the pathophysiologic mechanism of these disorders, and evaluation of new neurologic changes that occur perioperatively. The more commonly encountered neurologic disorders and their perioperative management are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEIZURE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least one million people in the United States have recurrent seizures or epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients with epilepsy are managed with antiepileptic drugs (AEDs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    People with epilepsy appear to be at significant risk of postoperative complications, some of which are attributed to epilepsy and some to comorbidities associated with epilepsy. In one retrospective database study, 13,103 patients with epilepsy had a higher rate of postoperative complications compared to those without epilepsy (OR = 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/2\">",
"     2",
"    </a>",
"    ]. Stroke was identified as the most significant postoperative complication in patients with epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Causes of seizures in perioperative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures can occur during the perioperative period due to a number of causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anesthesia",
"     </li>",
"     <li>",
"      Metabolic derangements",
"     </li>",
"     <li>",
"      Drug and alcohol withdrawal",
"     </li>",
"     <li>",
"      Intracranial surgery",
"     </li>",
"     <li>",
"      Underlying epilepsy, particularly when antiepileptic drugs have been stopped",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures that occur during surgery may be anesthetic related, but seizures that occur after surgery are generally not related to the effects of anesthesia and warrant investigation in patients without a known underlying seizure disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I (excitation) and Stage II (delirium) of anesthesia are the periods of greatest risk for seizure activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/3\">",
"     3",
"    </a>",
"    ]. Seizures associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    administration may occur during inhalation induction, on emergence, or during the postoperative period. Other anesthetics that may be associated with seizures include local anesthetic overdose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    in large doses or administered to patients receiving monoamine oxidase inhibitors, and injection of retrobulbar block for ophthalmic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    and halothane are potent anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of the risk of seizures in patients during general anesthesia was evaluated in a population-based study of 297 patients with epilepsy who underwent general anesthesia but not a neurosurgical or invasive neurodiagnostic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/6\">",
"     6",
"    </a>",
"    ]. Six patients (2 percent) had seizures, only one requiring intravenous therapy. Five of these were children &lt;13 years in age; thus the incidence in children was 3 percent and the incidence in adults was 0.8 percent. This study did not evaluate the incidence of anesthesia-related seizures in patients who did not have epilepsy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Metabolic derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who have perioperative seizures in the absence of underlying epilepsy have a metabolic derangement. As examples, hyponatremia may occur following transurethral surgery, and hypercalcemia is seen after thyroid or parathyroid surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .) In addition, acute organ failure from any cause and rapidly developing malignant hyperthermia may cause seizures. Sepsis can cause seizures and should be considered in any trauma patient with an obvious source of infection. Patients with seizures postoperatively should be screened for electrolyte abnormalities as guided by the operative procedure and the preoperative laboratory values.",
"   </p>",
"   <p>",
"    Seizures in this setting do not require antiepileptic drug treatment, rather correction of the causative metabolic abnormality. See appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Drug and alcohol withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures can occur following withdrawal from any sedative-hypnotic medication; alcohol and barbiturate withdrawal are common precipitants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, a toxicology screen is warranted in patients who suffer postoperative seizures without a history of previous seizure disorder.",
"   </p>",
"   <p>",
"    Alcohol withdrawal seizures are predominantly seen in patients with a long history of chronic alcoholism. They are characteristically generalized tonic-clonic convulsions that occur within 48 hours after the last drink; they may occur after only two hours of abstinence. Typically two to five convulsions occur and then do not recur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiepileptic medication is generally not required if the seizure is clearly a generalized withdrawal seizure; the seizure can be aborted with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    . Prophylaxis with long-term antiepileptic drugs is not indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an alcoholic patient may have a chronic seizure disorder secondary to frequent head trauma. A focal seizure suggests that there is an underlying structural brain pathologic condition that may be a substrate for epilepsy. An electroencephalogram (EEG) and neuroimaging can be helpful in unclear situations. The presence of a potential epileptic focus suggests the need for long-term antiepileptic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intracranial surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of seizures following intracranial surgery depends upon the underlying pathologic conditions, location, and the degree of brain retraction required to perform the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The incidence of postoperative seizures is about 25 percent in surgical procedures requiring extensive retraction. In patients with subarachnoid hemorrhage, seizures occur with the initial bleed and at the same time of rebleeding. The risk of seizures in patients with brain tumors is related to the type of the tumor; as examples, oligodendroglioma (81 percent), astrocytoma (66 percent), ependymoma (50 percent), glioblastoma (42 percent), meningioma (40 percent), and metastatic disease (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Location of the tumor is also important; seizures are more common with tumors around the motor cortex and less common in tumors involving the occipital cortex. Approximately 50 percent of patients with subdural empyema and 36 to 79 percent of patients with intracerebral abscesses experience seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medication management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major motor seizures that occur during a surgical procedure can increase morbidity and mortality. Thus, patients with preexisting seizure disorders generally need to have anticonvulsant medications continued perioperatively. Pure absence seizures pose little threat perioperatively; it is not as vital to continue antiepileptic drugs perioperatively in these patients. Patients with seizures that occur as a result of a reversible cause (metabolic disturbance, alcohol withdrawal) do not require antiepileptic drugs.",
"   </p>",
"   <p>",
"    A number of options are available for patients who require antiepileptic drugs during the perioperative period and in patients who cannot take oral medications.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    are available parenterally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .) Some drugs are available in suspensions that can be administered via nasogastric tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Phenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is the most frequently used parenteral antiepileptic drug. It must be administered in saline or lactated ringer solution at a rate no faster than 50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    to avoid hypotension and asystole. The loading dose is 15 to 18",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    followed by 4 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for maintenance in four divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who can take oral medications, a loading schedule of an initial 400 mg dose followed by 300 mg every two hours for a total of 1 gram will achieve a therapeutic range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    may be administered through a nasogastric tube; a suspension of phenytoin should be mixed with 10 mL of water and delivered through the nasogastric tube followed by a 30 mL water flush. Phenytoin should not be give intramuscularly or rectally because of erratic absorption.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     Fosphenytoin",
"    </a>",
"    sodium is a water soluble prodrug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    that can be administered intravenously and intramuscularly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/14\">",
"     14",
"    </a>",
"    ]. It is tolerated better than phenytoin at the injection site. A loading dose of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    can be given at a rate of 150",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/14\">",
"     14",
"    </a>",
"    ]. Fosphenytoin may be administered intramuscularly when intravenous access is a problem.",
"   </p>",
"   <p>",
"    Regardless of the mode of administration, appropriate serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    should be followed in all patients. A level of 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is appropriate in patients with normal renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    can be administered in parenteral form. It is given in a 2 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose and 1 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day maintenance in divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/12\">",
"     12",
"    </a>",
"    ]. It also can be given intramuscularly or orally.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    sodium is available in a parenteral form; it should be administered over one hour at a rate no faster than 20",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"    Intravenous and oral forms are approximately dose-equivalent. Valproic acid syrup also can be given rectally in the same dosage as orally (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in divided doses). Suspensions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and valproic acid can be given via nasogastric tube.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are other options for acute management of seizures.",
"   </p>",
"   <p>",
"    There are no parenteral forms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The use of these medications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PARKINSON DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremor, rigidity, bradykinesia, and impaired postural reflexes are cardinal manifestations of Parkinson disease. Another important clinical manifestation is autonomic dysfunction manifested by orthostatic hypotension, inability to control temperature, abnormal sweating, and sialorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major perioperative issues in patients with Parkinson disease are assessments of swallowing and pulmonary function, correct application of antiparkinsonian medications, and maintenance of volume status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Swallowing abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of swallowing abnormalities have been identified in parkinsonian patients such as abnormal lingual control of swallowing, lingual festination in which the elevated tongue prevents passage of the bolus of food into the pharynx, delayed swallowing reflex with reduced pharyngeal peristalsis and aspiration, repetitive and involuntary reflux from the vallecula and piriform sinuses into the oral cavity, and difficulty swallowing pills with retention in the vallecula.",
"   </p>",
"   <p>",
"    Most patients with moderate to severe Parkinson disease have one or more of these abnormalities, which may or may not respond to antiparkinsonian medication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Patients with moderate to severe Parkinson disease and patients who complain of swallowing difficulties should have a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow done preoperatively. If an abnormality exists, patients can be taught preoperatively the voluntary airway protection technique in which they are instructed to hold their breath, tilt the chin to the chest, swallow, cough, and then swallow again. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\", section on 'Swallowing rehabilitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigidity and bradykinesia of the respiratory muscles puts patients with Parkinson disease at risk for postoperative pulmonary complications. Kyphosis, pharyngeal dysfunction, and sialorrhea may further compound the restrictive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperatively, pulmonary function tests and arterial blood gas determinations are obtained to assess the degree of impairment. Postoperative management includes incentive spirometry, postural drainage, percussion, and reinstitution of antiparkinsonian medications. An uncontrolled trial found that levodopa improved the minute ventilation and vital capacity in patients with Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Perioperative medication management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Parkinson disease present several challenges related to medication management in the perioperative period. Abrupt withdrawal of anti-Parkinson drugs may to lead to flares of Parkinson symptoms and, rarely, the neuroleptic malignant syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuroleptic malignant syndrome\", section on 'Antiparkinson medication withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     Carbidopa-levodopa",
"    </a>",
"    has a short duration of action and can be given the night before surgery, and even on the day of surgery itself if operation is scheduled for later in the day. Dopamine agonists (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ) can usually also be continued close to the time of surgery. They should be resumed as early as possible after the operation (with sips of water or by nasogastric tube).",
"   </p>",
"   <p>",
"    For patients with dysphagia, orally disintegrating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (Parcopa) is a potential treatment option.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     Benztropine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    are anticholinergic drugs that are available in parenteral form and can be used in patients who are unable to take oral medication, but they should be used in as low a dose as possible as they may precipitate an acute confusional state, especially in the elderly. All antiparkinsonian medications are active in the central nervous system and can cause an alteration in mental status, as well as side effects such as involuntary movements (dyskinesias), dizziness, hallucinations, dystonia, confusion, somnolence, and insomnia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative nausea and vomiting may require treatment but in parkinsonian patients, phenothiazines, which are centrally acting dopamine antagonists, should be avoided.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    (for postoperative analgesia) should be avoided in patients taking MAO-B inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Early mobilization and physical therapy are also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MYASTHENIA GRAVIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative management of patients with myasthenia gravis requires careful thought and planning. Myasthenic crisis with respiratory failure is the most concerning complication in the perioperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of myasthenia gravis\", section on 'Myasthenic crisis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link&amp;anchor=H8#H8\">",
"     \"Thymectomy for myasthenia gravis\", section on 'Perioperative considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Medication management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medication regimen can be complex; patients with myasthenia usually are taking anticholinesterase medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , and may also be taking chronic immunosuppressive agents such as corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or less commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    can be held on the morning of surgery in patients with myasthenia to avoid muscarinic side effects and to decrease the need for muscle relaxants, but some physicians choose to continue it for psychological support [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/22\">",
"     22",
"    </a>",
"    ]. Some patients take a long-acting preparation of pyridostigmine at bedtime (Mestinon Timespans); a short-acting form should be substituted the night before surgery. Anticholinesterase medications are usually restarted when the patient is hemodynamically stable at the patient's usual dose. Parenteral substitution also is available for these agents. When used intramuscularly",
"    <span class=\"nowrap\">",
"     1/10th",
"    </span>",
"    the usual oral dose is substituted; when used intravenously,",
"    <span class=\"nowrap\">",
"     1/30th",
"    </span>",
"    the usual oral dose is administered by slow IV push or a continuous infusion can be initiated at 2",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Since some patients with myasthenia gravis are on high doses of corticosteroids, parenteral substitution is advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of action of other oral immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is usually several months. There are no published data to guide management of these drugs around the time of surgery. Although parenteral substitution is possible for both cyclosporine and azathioprine, they likely can be held on the morning of surgery given the long duration of effect. These agents can be resumed when the patient is taking oral medication safely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drugs that may exacerbate myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the recognition that some medications can cause a significant increase in weakness in patients with MG (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    ). These include aminoglycoside antibiotics, beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/23\">",
"     23",
"    </a>",
"    ]. A number of other drugs may unmask or exacerbate MG, particularly the neuromuscular blocking agents used during anesthesia, which can lead to prolonged postoperative weakness and ventilator dependence. These should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of myasthenia gravis\", section on 'Drugs that may exacerbate myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MALIGNANT HYPERTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant hyperthermia (MH) is a rare complication of general anesthesia, most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    and halothane [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/24\">",
"     24",
"    </a>",
"    ]. After exposure to inhaled anesthetics or depolarizing muscle relaxants, susceptible individuals experience a hypermetabolic state characterized by tachycardia, hyperpyrexia, fluctuation in blood pressure, metabolic and respiratory acidosis, cyanosis, and muscle rigidity. Multiple organ failure and death may result if the entity is not recognized and treated promptly.",
"   </p>",
"   <p>",
"    The clinical diagnosis and management of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal muscle rigidity and difficulty with intubation, rather than a flaccid paralysis with anesthesia induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , characterizes an acute reaction. This frequently begins in the masseter muscles.",
"   </p>",
"   <p>",
"    The most consistent early feature of an MH crisis is persistent sinus tachycardia; this occurs in 90 percent of the cases within 30 minutes of anesthesia induction. Ventricular tachycardia may also occur.",
"   </p>",
"   <p>",
"    Instability of the systolic blood pressure secondary to increased cardiac output and arteriolar spasm results in hypertension. Hypotension occurs before cardiac arrest. The hypercatabolic state produces rapid, deep respirations and increased body temperature. A rise in the PCO2 is the first parameter that may be noticed. There is concomitant respiratory acidosis and metabolic acidosis (lactic acidosis). Frequently, there is a transient dilatation of the vascular smooth muscle, resulting in a flush on the anterior chest. This is followed by vascular spasm and cyanosis that is not reversible with 100 percent oxygen. The rise in temperature is due to both an increase in heat production and a decrease in heat loss from the peripheral vasospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment in MH includes supportive therapy, cooling measures, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"     dantrolene",
"    </a>",
"    sodium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/8\">",
"     8",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease is an important issue in many surgical patients, particularly the elderly. The medical consultant may be asked to make recommendations regarding the timing of elective surgery in patients who have had a stroke, or to make recommendations in patients with known or suspected cerebrovascular disease. In addition, the presence of cerebrovascular disease is often a marker for coexisting cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patients with a history of stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, at least two weeks should elapse after a stroke before elective surgery is attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/25\">",
"     25",
"    </a>",
"    ]. We recommend evaluation of the carotid arteries and urgent surgical repair in patients having recurrent transient ischemic attacks (TIAs) due to an identified carotid lesion.",
"   </p>",
"   <p>",
"    Patients with a history of an embolic stroke due to valvular heart disease, prosthetic valves, or atrial fibrillation are frequently maintained on long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The management of these patients perioperatively is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Perioperative stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative stroke is an infrequent complication of general surgical procedures, occurring at a rate of 0.3 to 3.5 percent depending upon the age of the patient and other complicating factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients undergoing aortoiliac surgery who are at additional risk because of generalized atherosclerosis and intraoperative hypotension have a perioperative stroke rate of 1 percent.",
"   </p>",
"   <p>",
"    Strokes most commonly occur in the postoperative period. One study, for example, found that 83 percent of strokes occurred postoperatively and 17 percent occurred during the operative period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/27\">",
"     27",
"    </a>",
"    ]. Approximately one-third of cases are due to cardiogenic embolism with atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Asymptomatic carotid bruit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid stenosis is associated with an increased risk of perioperative stroke in general surgical populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. As an example, one study of 224 patients with carotid stenosis documented by carotid ultrasound prior to general surgery reported a perioperative stroke risk of 3.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/29\">",
"     29",
"    </a>",
"    ]. This risk is similar to the risk of stroke associated with carotid endarterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link\">",
"     \"Carotid endarterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More commonly, however, the patient does not have a history of carotid stenosis, but the medical consultant discovers an asymptomatic carotid bruit on a preoperative physical examination. Asymptomatic carotid bruits occur in about 4 percent of the population older than 40 years; one group found that 14 percent of all surgical patients older than 55 years had carotid bruits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A bruit alone is a poor predictor of underlying carotid stenosis; only 40 to 60 percent of asymptomatic patients with audible cervical bruits will have hemodynamically significant internal carotid lesions by noninvasive studies or arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The risk for a stroke in patients with an asymptomatic carotid bruit is approximately 2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for asymptomatic carotid artery stenosis\", section on 'Carotid bruit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an increase in perioperative stroke has not been demonstrated in patients with asymptomatic carotid bruits undergoing noncardiac surgery. As a result, further evaluation of the carotid arteries in patients with an asymptomatic carotid bruit is not warranted in these situations.",
"   </p>",
"   <p>",
"    Carotid artery disease in patients undergoing coronary artery bypass graft (CABG) has been the subject of considerable study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/36\">",
"     36",
"    </a>",
"    ]. The incidence of perioperative stroke is not altered by CEA in patients who only have an asymptomatic carotid bruit noted prior to CABG. As an example, one study compared 132 patients who underwent combined CEA and CABG procedures with 167 patients with carotid artery disease who underwent only elective CABG; the most common indication for a combined CEA and CABG was an asymptomatic bruit (67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/37\">",
"     37",
"    </a>",
"    ]. There was no difference in mortality (3 percent) between the combined CEA and CABG and CABG-only groups; the rate of stroke was similar in the combined surgery group and those undergoing CABG-only who had an asymptomatic bruit (1.6 versus 3.3 percent). In contrast, the stroke rate was lower in the combined surgery group than the CABG-only group for those with a history of stroke or TIA (8.6 percent).",
"   </p>",
"   <p>",
"    These results suggest that CEA is not necessary before or at the same time as CABG for most patients with an asymptomatic carotid bruit. However, patients with an asymptomatic bruit who have severe carotid stenosis may represent an exception. This was illustrated in a study of 68 patients with 80 to 99 percent carotid stenosis undergoing CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/38\">",
"     38",
"    </a>",
"    ]. There were no neurologic events in those undergoing combined CEA and CABG compared with a 20 percent incidence of permanent neurologic defect in those undergoing CABG alone. The results were the same in a second study of 129 patients with &ge;80 percent carotid stenosis, 114 of whom underwent staged or combined CEA and CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the following general approach should be considered in patients with an asymptomatic carotid bruit noted preoperatively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Further investigation is not necessary in patients undergoing noncardiac surgery because of the relatively poor correlation between bruits and the presence of carotid artery disease, and the relatively low perioperative stroke risk even in patients with known carotid stenosis.",
"     </li>",
"     <li>",
"      A carotid Doppler study appears to be warranted in patients undergoing CABG who have a carotid bruit because of the reduced risk of combined CEA and CABG compared with CABG alone in patients with severe carotid stenosis (&gt;70 to 80 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=see_link\">",
"       \"Coronary artery bypass grafting in patients with cerebrovascular disease\"",
"      </a>",
"      .) Patients with a history of stroke or TIA should also undergo a noninvasive evaluation of the carotid arteries prior to CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Vertebrobasilar disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the risk of perioperative stroke in patients with vertebrobasilar disease. One study of 50 operations performed under general anesthesia in 38 patients with a history of symptomatic vertebrobasilar ischemia found that three patients had ischemic strokes in the vertebrobasilar territory immediately after surgery (rate 6.0 percent per procedure, 95% CI 1.2-16.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Relationship to cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong association between carotid artery disease and coronary artery disease; patients with carotid artery disease are more likely to die from ischemic heart disease than cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/34,41\">",
"     34,41",
"    </a>",
"    ]. Aggregate data show a consistently higher percentage of cardiac deaths than stroke deaths following TIAs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/42\">",
"     42",
"    </a>",
"    ]. Approximately 70 percent of all late deaths following CEA are due to cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/43\">",
"     43",
"    </a>",
"    ]. The cardiac death rate is approximately 5 percent per year for patients with asymptomatic carotid bruits, TIAs, or stroke. Thirty-five percent of patients with symptomatic cerebrovascular disease or symptomatic carotid bruits have coronary artery disease that may be inoperable or warrant myocardial revascularization, and many of these patients do not have cardiac symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the presence of known carotid artery disease or a carotid bruit should be a signal that the patient may have coexisting coronary heart disease. The best approach for identifying coronary heart disease in patients with asymptomatic carotid artery disease needs further evaluation. Coronary angiography is recommended in patients with an abnormal electrocardiogram or angina pectoris. Noninvasive approaches are probably adequate in other situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CHANGE IN MENTAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical consultant is frequently asked to see a postoperative patient for a change in mental status. The two major considerations are the presence of structural central nervous system disease or metabolic derangement.",
"   </p>",
"   <p>",
"    Delirium or a confusional state may develop in the immediate postoperative period as the patient emerges from anesthesia, or it may follow lucid intervals for several days. Delirium in hospitalized patients increases the length of stay, risk of complications, mortality, and institutionalization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Acute toxic metabolic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute toxic metabolic encephalopathy, which encompasses delirium and the acute confusional state, is a condition of acute global cerebral dysfunction not due to primary structural brain disease. The \"confusional state\" implies an alteration in attentiveness, with the patient being unable to maintain a cohesive train of thought. This is part of a broader clinical spectrum that ranges from lack of attention, to agitation, to lethargy proceeding to coma. The term delirium is frequently used to define a confusional state with superimposed hyperactivity of the sympathetic limb of the autonomic nervous system with consequent tremor, tachycardia, diaphoresis, and mydriasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Etiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of postoperative confusion or delirium is increased in the following patient groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with pre-existing brain disease have deficits in perception and processing of information that limit coping mechanisms, frequently leading to illusions, hallucinations, and paranoia after a surgical procedure.",
"     </li>",
"     <li>",
"      Patients with seizure disorders who stop anticonvulsants perioperatively may become confused, particularly if they are having nonconvulsive seizures.",
"     </li>",
"     <li>",
"      Patients who have an addiction to drug or alcohol are also at risk; it is not uncommon to see delirium tremens precipitated by a cessation of alcohol during the surgical procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Porphyria, hypothyroidism, and cancer are all diseases that predispose to postoperative deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/49-51\">",
"       49-51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type of operation also influences the risk of delirium or confusion. Up to one-third of patients may develop delirium after cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link&amp;anchor=H13#H13\">",
"     \"Neurologic complications of cardiac surgery\", section on 'Delirium'",
"    </a>",
"    .) The incidence of delirium is also increased in patients who have an eye patch after ophthalmic surgery, the so called \"black patch delirium.\" The incidence of delirium after surgical eye patching is approximately 16 percent, or higher in patients with preexisting brain disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/54\">",
"     54",
"    </a>",
"    ]. Delirium occurs in as many as 61 percent of patients with hip fracture; over half of cases occur postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/58/33706?source=see_link\">",
"     \"Medical consultation for patients with hip fracture\"",
"    </a>",
"    .) Confusional states are also common following elective total hip replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/57\">",
"     57",
"    </a>",
"    ]. Burn victims, women having abortion or hysterectomy, transplant patients, and those with chronic pain are also at high risk for delirium.",
"   </p>",
"   <p>",
"    Sepsis is a common cause of postoperative mental status change. Numerous metabolic derangements are associated with sepsis, including a hyperdynamic circulation, hypercatabolic state, and altered hormonal patters with elevated catecholamine levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .) The encephalopathy of sepsis may include hyperventilation, fever, seizures, focal or nonfocal examination, and a diffusely slow EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of medications are associated with delirium (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A number of metabolic derangements can cause a change in mental status or a confusional state (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confused or delirious patients are frequently disoriented to person, place, date, and time. They are also unable to remember four objects in three minutes and are unable to perform serial subtractions. Perceptual changes with illusions and visual hallucinations can occur.",
"   </p>",
"   <p>",
"    There are several characteristic clinical signs of a toxic metabolic encephalopathy, including tremor, asterixis, and multifocal myoclonus. The tremor and asterixis occur after a latent period of 20 to 36 seconds with postural fixation, the tremor appearing first.",
"   </p>",
"   <p>",
"    The tremor has two separate components: the first is a varying oscillation of the fingers, usually in the anterior posterior direction, but with a rotator component at the wrist; the second is a tiny, but clearly defined, random motion of the fingers at the metacarpophalangeal joint from one to two times per second. Usually the tremor increases in amplitude while the hands remain dorsiflexed. The oscillation becomes wider and more variable and the tiny finger motions become more rapid than propulsive, followed by the hand with the fingers leading (by 2 to 5 cm), only to be jerked to the hands' original position. This produces the characteristic asterixis (flap).",
"   </p>",
"   <p>",
"    Patients have no control over these movements and have no warning of their occurrence. The flaps may be synchronous or asynchronous. Commonly, one flap of asterixis is followed in quick succession by two to three others, followed by a return to the original fixed posture with amelioration of the tremor. This then repeats over and over.",
"   </p>",
"   <p>",
"    Asterixis with the tremor is seen in a variety of metabolic encephalopathies, including uremia, hypokalemia, polycythemia, congestive heart failure, chronic obstructive pulmonary disease with carbon dioxide narcosis, hepatic failure, idiopathic steatorrhea, Whipple disease and other malabsorption syndromes, magnesium deficiency, bromide intoxication, and a variety of other potentially toxic compounds, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/2/35878?source=see_link\">",
"     chlorothiazide",
"    </a>",
"    , and methionine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/61\">",
"     61",
"    </a>",
"    ]. Rarely, asterixis can be seen in structural nervous system disease involving the thalamus or parietal lobe in these cases, the asterixis is associated with a severe loss of position sense [",
"    <a class=\"abstract\" href=\"UTD.htm?10/9/10394/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multifocal myoclonus is a sudden nonrhythmic, nonpattern, and gross twitching of various muscle groups in the body. Myoclonus may occur in a single fascicle of muscle, without displacement of a joint; in a muscle in its entirety; or in a group of muscles, with gross movement of the attached structures or limb. It is either a single muscle contraction or a series of them, the latter being an irregular pattern of movement occurring in a rhythmic sequence or a rhythmic unpatterned succession of contractions with each muscle acting in disorderly relation to the others. Multifocal myoclonus can be prominent in the face muscles and the tongue. It indicates a severe metabolic disturbance that may or may not be reflected in the EEG. Occasionally, this myoclonus can be brought on a startle response such as elicited with a sudden clap or a loud noise. The myoclonus frequently disappears with appropriate treatment of the encephalopathy.",
"   </p>",
"   <p>",
"    The pupillary light response to bright light is generally preserved in metabolic encephalopathies, even in the face of profound coma. There are certain exceptions to this; glutethimide, methaqualone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    poisoning and amphetamine overdoses are notorious for producing large pupils. Large, fixed pupils can also occur with high doses of dopamine. Opiates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    drops produce a constricted or pinpoint pupil.",
"   </p>",
"   <p>",
"    Almost all types of eye positioning or movement can be observed in metabolic encephalopathy. Downward conjugate gaze and random roving eye movements are frequently seen. Persistent conjugate lateral deviation suggests structural brain or brainstem disease. Ice water placed in the ear after examination to make sure there are no structural abnormalities in the ear canal produces tonic conjugate deviation toward the ear containing the ice water in patients with an intact brainstem. This oculovestibular reflex can be lost in hypothermia and in massive sedative hypnotic overdoses.",
"   </p>",
"   <p>",
"    Changes in tone, focal weakness, and decerebrate and decorticate posturing can all occur with diffuse toxic metabolic encephalopathy. Frequently, one can elicit Frontal release signs, paratonia, grasp, rooting, and suck, also are frequently present.",
"   </p>",
"   <p>",
"    Focal or generalized convulsions can occur with all metabolic derangements. The seizures may be extremely difficult to control, particularly until the metabolic derangement is corrected, or if there is any underlying hypoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with a postoperative change in mental status is based upon knowledge of the patient's preoperative baseline. Confusion and disorientation postoperatively can be anticipated in patients who have underlying brain or psychiatric disease, and the patient can be supported appropriately.",
"   </p>",
"   <p>",
"    More commonly, the change in mental status is an acute event in the postoperative period. Toxic metabolic encephalopathy is a diagnosis of exclusion with a broad differential diagnosis. The basic approach to the patient includes a physical examination, metabolic screening, and imaging studies (",
"    <a class=\"graphic graphic_figure graphicRef72084 \" href=\"UTD.htm?4/18/4399\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physical examination helps assess ongoing underlying changes. Changes in vital signs and asterixis, tremor, and myoclonus are all physical signs of underlying metabolic problems. The neurologic examination generally can demonstrate focal structural disease, suggestive of a structural abnormality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      .) This may be manifested by cranial nerve findings, subtle motor weakness, or abnormal postures. Perioperative strokes generally result in a focal examination, although there are silent areas in which focal signs are not easily discernible.",
"     </li>",
"     <li>",
"      Laboratory studies should include an arterial blood gas, electrolytes, blood urea nitrogen and creatinine, a complete blood count, and liver function tests. Abnormalities in serum calcium, phosphorus, and magnesium also can alter mental status and produce a confusional state.",
"     </li>",
"     <li>",
"      Ancillary evidence from imaging techniques, such as a CT scan or MRI scan, are helpful in the diagnosis of structural disease, especially in the frontal and temporal lobes, which may be relatively silent areas on physical examination. CT or MRI are primarily indicated in the presence of focal signs on neurologic examination, although should be considered in all patients in whom a diagnosis is not otherwise determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the first tasks while awaiting screening laboratory studies is the assessment of the concurrent medications. The most common cause of a change in mental status, other than sepsis and electrolyte abnormalities, is probably the medication given for sedation. Anticholinergic medicines have long been implicated as causes of confusional states, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , phenothiazines, antihistamines, hypnotics, barbiturates, and analgesics. Other drugs that can cause confusion include corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , which can impair the metabolism of other medications by inhibiting the hepatic microsomal system. Anesthetics, such as halothane, can produce headache, ataxia, and lethargy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     Enflurane",
"    </a>",
"    has epileptogenic capacity, and, when given to a patient with epilepsy can precipitate seizures.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    can produce hallucinations, particularly in younger patients. Opioids, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , can induce seizures and changes in mental status. The first approach to these patients is to stop all the sedative hypnotics and analgesics, at least to the point of pain tolerance.",
"   </p>",
"   <p>",
"    Although the typical course of delirium or confusion lasts one to two days, it may last longer, especially in patients with underlying structural brain disease. Caring for these types of patients is extremely difficult. Patients may have difficulty communicating their symptoms and may have totally unpredictable behavior. The patient may be agitated, hypervigilant, fearful, and paranoid, or alternatively sluggish, lethargic, and obtunded. Alterations between these two extremes are common. The general management of patients with toxic metabolic encephalopathy and delirium are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25195547\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seizures that occur during the perioperative period may be anesthetic related, due to metabolic derangements, drug and alcohol withdrawal, and intracranial surgery. They may also arise from premorbid epilepsy, particularly when antiepileptic drug (AED) therapy has been disrupted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Seizure disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Seizures that occur during a surgical procedure can increase morbidity and mortality.",
"     </li>",
"     <li>",
"      Patients with preexisting seizure disorders generally need to have anticonvulsant medications continued perioperatively, with as little disruption as possible.",
"     </li>",
"     <li>",
"      Patients with perioperative seizures that occur as a result of a known reversible cause (metabolic disturbance, alcohol withdrawal) do not require antiepileptic drugs; the underlying condition should be treated.",
"     </li>",
"     <li>",
"      Other patients with new-onset perioperative seizures should probably be treated with AED therapy while the underlying cause is evaluated.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      is the most frequently used parenteral antiepileptic drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major perioperative issues in patients with Parkinson disease are impaired swallowing and pulmonary function potentially leading to pneumonia. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      (for postoperative analgesia) should be avoided in patients taking MAO-B inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Parkinson disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with myasthenia gravis, myasthenic crisis with respiratory failure is the most concerning complication in the perioperative period. The medication regimen should be disrupted as little as possible and medications that can exacerbate myasthenia should be avoided (",
"      <a class=\"graphic graphic_table graphicRef62302 \" href=\"UTD.htm?11/61/12254\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Myasthenia gravis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=see_link&amp;anchor=H8#H8\">",
"       \"Thymectomy for myasthenia gravis\", section on 'Perioperative considerations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perioperative stroke is an infrequent but feared complication of surgery:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a history of stroke are at increased risk perioperative stroke. Surgery should be deferred in the immediate post-stroke period if possible, the underlying cause of stroke should be evaluated and corrected if possible. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Patients with a history of stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with asymptomatic carotid stenosis are at somewhat increased risk of perioperative stroke. An increase in perioperative stroke has not been demonstrated in patients with asymptomatic carotid bruits undergoing noncardiac surgery. Further evaluation of the carotid arteries in patients with an asymptomatic carotid bruit is not warranted, however, the presence of known carotid artery disease or a carotid bruit should be a signal that the patient may have coexisting coronary heart disease (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Asymptomatic carotid bruit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with comorbid carotid and coronary artery disease is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=see_link\">",
"       \"Coronary artery bypass grafting in patients with cerebrovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative delirium may develop in the immediate postoperative period as the patient emerges from anesthesia, or it may follow lucid intervals for several days. Postoperative delirium may be caused by sepsis, medications and a number of metabolic derangements. Delirium in hospitalized patients increases the length of stay, risk of complications, mortality, and postdischarge institutionalization. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Change in mental status'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The risk of postoperative confusion or delirium is increased in the following patient groups (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with pre-existing brain disease have deficits in perception and processing of information that limit coping mechanisms, frequently leading to illusions, hallucinations, and paranoia after a surgical procedure.",
"     </li>",
"     <li>",
"      Patients with seizure disorders who stop medications before surgery may become confused, particularly if they are having nonconvulsive seizures.",
"     </li>",
"     <li>",
"      Patients who have an addiction to drug or alcohol are also at risk; it is not uncommon to see delirium tremens precipitated by a cessation of alcohol during the surgical procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cancer and other medical comorbidities may also increase the risk of postoperative delirium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delirium is characterized by confusion, poor memory and attention and fluctuating alertness. Perceptual changes with illusions and visual hallucinations can occur. tremor, asterixis, and multifocal myoclonus. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation and management of patients with postoperative delirium focuses on obtaining laboratory studies, evaluating and correcting metabolic derangements, systemic complications and possible medications. Imaging studies and EEG are not necessary in most patients but may be indicated in those whose cause of delirium remains obscure to exclude structural brain disease or nonconvulsive seizures as a possible contributor or cause of neurologic change. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Approach to the patient'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Resolution of symptoms may lag behind treatment of underlying cause, particularly if there is underlying neurodegenerative or structural brain disease. Treatment of delirium is discussed separately. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Approach to the patient'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"       \"Prevention and treatment of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/1\">",
"      Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/2\">",
"      Chang CC, Hu CJ, Lam F, et al. Postoperative adverse outcomes in surgical patients with epilepsy: a population-based study. Epilepsia 2012; 53:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/3\">",
"      Evans DE. Anaesthesia and the epileptic pateint. A review. Anaesthesia 1975; 30:34.",
"     </a>",
"    </li>",
"    <li>",
"     Bell RD. Perioperative seizures in decision making. In: Anesthesiology, Bready LL, Smith RB.  (Eds), BC Decker, Toronto 1987. p.224.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/5\">",
"      Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part I). Anesth Analg 1990; 70:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/6\">",
"      Benish SM, Cascino GD, Warner ME, et al. Effect of general anesthesia in patients with epilepsy: a population-based study. Epilepsy Behav 2010; 17:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/7\">",
"      Sampliner R, Iber FL. Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study. JAMA 1974; 230:1430.",
"     </a>",
"    </li>",
"    <li>",
"     Bell R, Merli G. Perioperative assessment and management of the surgical patient with neurologic problems. In: Medical Management of the Surgical Patient, Merli G, Weitz H.  (Eds), Saunders Elsevier, Philadelphia 2008. p.535.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/9\">",
"      Lee ST, Lui TN, Chang CN, et al. Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 1989; 31:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/10\">",
"      Shaw MD, Foy PM. Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper. J R Soc Med 1991; 84:221.",
"     </a>",
"    </li>",
"    <li>",
"     Epilepsy Foundation of America. Origins and classification of epilepsia. In: Basic statistics on the epilepsia, FA Davis, Philadelphia 1975. p.16.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/12\">",
"      Penry JK, Newmark ME. The use of antiepileptic drugs. Ann Intern Med 1979; 90:207.",
"     </a>",
"    </li>",
"    <li>",
"     Seizure Disorders. A Pharmacological Approach to Treatment, Wilder BJ, Bruni M.  (Eds), Raven Press, New York 1981.",
"    </li>",
"    <li>",
"     AHFS Drug Information 2000, American Society of Health-System Pharmacists Inc. Bethseda, MD, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/15\">",
"      Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson's disease. Neurology 1986; 36:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/16\">",
"      Mutch WJ, Strudwick A, Roy SK, Downie AW. Parkinson's disease: disability, review, and management. Br Med J (Clin Res Ed) 1986; 293:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/17\">",
"      Meir, M. Mechanism leading to hypoventilation in extrapyramidal disorders with special reference to Parkinson's disease. J Am Geriatr Soc 1976; 15:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/18\">",
"      Paulson GD, Tafrate RH. Some \"minor\" aspects of parkinsonism, especially pulmonary function. Neurology 1970; 20:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/19\">",
"      Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 1985; 254:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/20\">",
"      Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001; 16:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/21\">",
"      Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999; 52:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/22\">",
"      Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. Mt Sinai J Med 2002; 69:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/23\">",
"      Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med 1997; 157:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/24\">",
"      Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/25\">",
"      Sundt TM, Sandok BA, Whisnant JP. Carotid endarterectomy. Complications and preoperative assessment of risk. Mayo Clin Proc 1975; 50:301.",
"     </a>",
"    </li>",
"    <li>",
"     Bell R, Merli G. Perioperative assessment and management of the surgical patient with neurologic problems. In: Medical Management of the Surgical Patient, Merli G, Weitz H.  (Eds), W. B. Saunders, Philadelphia 1998. p.283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/27\">",
"      Hart R, Hindman B. Mechanisms of perioperative cerebral infarction. Stroke 1982; 13:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/28\">",
"      Kartchner MM, McRae LP. Carotid occlusive disease as a risk factor in major cardiovascular surgery. Arch Surg 1982; 117:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/29\">",
"      Evans BA, Wijdicks EF. High-grade carotid stenosis detected before general surgery: is endarterectomy indicated? Neurology 2001; 57:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/30\">",
"      Ropper AH, Wechsler LR, Wilson LS. Carotid bruit and the risk of stroke in elective surgery. N Engl J Med 1982; 307:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/31\">",
"      Kartchner MM, McRae LP. Guidelines for noninvasive evaluation of asymptomatic carotid bruits. Clin Neurosurg 1981; 28:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/32\">",
"      David TE, Humphries AW, Young JR, Beven EG. A correlation of neck bruits and arteriosclerotic carotid arteries. Arch Surg 1973; 107:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/33\">",
"      Rea T. The role of carotid bruit in screening for carotid stenosis. Ann Intern Med 1997; 127:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/34\">",
"      Heyman A, Wilkinson WE, Heyden S, et al. Risk of stroke in asymptomatic persons with cervical arterial bruits: a population study in Evans County, Georgia. N Engl J Med 1980; 302:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/35\">",
"      Wolf PA, Kannel WB, Sorlie P, McNamara P. Asymptomatic carotid bruit and risk of stroke. The Framingham study. JAMA 1981; 245:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/36\">",
"      Reed GL 3rd, Singer DE, Picard EH, DeSanctis RW. Stroke following coronary-artery bypass surgery. A case-control estimate of the risk from carotid bruits. N Engl J Med 1988; 319:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/37\">",
"      Jones EL, Craver JM, Michalik RA, et al. Combined carotid and coronary operations: when are they necessary? J Thorac Cardiovasc Surg 1984; 87:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/38\">",
"      Hines GL, Scott WC, Schubach SL, et al. Prophylactic carotid endarterectomy in patients with high-grade carotid stenosis undergoing coronary bypass: does it decrease the incidence of perioperative stroke? Ann Vasc Surg 1998; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/39\">",
"      Gott JP, Thourani VH, Wright CE, et al. Risk neutralization in cardiac operations: detection and treatment of associated carotid disease. Ann Thorac Surg 1999; 68:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/40\">",
"      Blacker DJ, Flemming KD, Wijdicks EF. Risk of ischemic stroke in patients with symptomatic vertebrobasilar stenosis undergoing surgical procedures. Stroke 2003; 34:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/41\">",
"      Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986; 315:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/42\">",
"      Graor RA, Hetzer NR. Management of coexistent carotid artery and coronary artery disease. Stroke 1988; 19:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/43\">",
"      Whisnant JP, Sandok BA, Sundt TM Jr. Carotid endarterectomy for unilateral carotid system transient cerebral ischemia. Mayo Clin Proc 1983; 58:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/44\">",
"      Francis J, Kapoor WN. Prognosis after hospital discharge of older medical patients with delirium. J Am Geriatr Soc 1992; 40:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/45\">",
"      Levkoff SE, Evans DA, Liptzin B, et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 1992; 152:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/46\">",
"      Murray AM, Levkoff SE, Wetle TT, et al. Acute delirium and functional decline in the hospitalized elderly patient. J Gerontol 1993; 48:M181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/47\">",
"      Rockwood K. Delays in the discharge of elderly patients. J Clin Epidemiol 1990; 43:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/48\">",
"      Cole MG, Primeau F, McCusker J. Effectiveness of interventions to prevent delirium in hospitalized patients: a systematic review. CMAJ 1996; 155:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/49\">",
"      Steen PA, Michenfelder JD. Neurotoxicity of anesthetics. Anesthesiology 1979; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/50\">",
"      Ladenson PW, Levin AA, Ridgway EC, Daniels GH. Complications of surgery in hypothyroid patients. Am J Med 1984; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/51\">",
"      Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 1983; 34:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/52\">",
"      Kornfeld DS, Heller SS, Frank KA, Moskowitz R. Personality and psychological factors in postcardiotomy delirium. Arch Gen Psychiatry 1974; 31:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/53\">",
"      Smith LW, Dimsdale JE. Postcardiotomy delirium: conclusions after 25 years? Am J Psychiatry 1989; 146:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/54\">",
"      Summers WK, Reich TC. Delirium after cataract surgery: review and two cases. Am J Psychiatry 1979; 136:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/55\">",
"      Brauer C, Morrison RS, Silberzweig SB, Siu AL. The cause of delirium in patients with hip fracture. Arch Intern Med 2000; 160:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/56\">",
"      Gustafson Y, Berggren D, Br&auml;nnstr&ouml;m B, et al. Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc 1988; 36:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/57\">",
"      Sheppeard H, Cleak DK, Ward DJ, O'Connor BT. A review of early mortality and morbidity in elderly patients following Charnley total hip replacement. Arch Orthop Trauma Surg 1980; 97:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/58\">",
"      Hasselgren PO, Fischer JE. Septic encephalopathy. Etiology and management. Intensive Care Med 1986; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/59\">",
"      Jackson AC, Gilbert JJ, Young GB, Bolton CF. The encephalopathy of sepsis. Can J Neurol Sci 1985; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     Bell, RD, Lastimosa, ACB. Metabolic encephalopathies. In: Neurology, Rosenberg, RN (Ed), Grune &amp; Stratton, New York 1980. p.115.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/61\">",
"      CONN HO. Asterixis in non-hepatic disorders. Am J Med 1960; 29:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/9/10394/abstract/62\">",
"      LEAVITT S, TYLER HR. STUDIES IN ASTERIXIS. I. Arch Neurol 1964; 10:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4827 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10394=[""].join("\n");
var outline_f10_9_10394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25195547\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEIZURE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Causes of seizures in perioperative patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Metabolic derangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Drug and alcohol withdrawal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intracranial surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medication management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Phenytoin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PARKINSON DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Swallowing abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MYASTHENIA GRAVIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Medication management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drugs that may exacerbate myasthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MALIGNANT HYPERTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CEREBROVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patients with a history of stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Perioperative stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Asymptomatic carotid bruit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Vertebrobasilar disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Relationship to cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CHANGE IN MENTAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Acute toxic metabolic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25195547\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4827|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/18/4399\" title=\"figure 1\">",
"      Postop neurologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4827|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12254\" title=\"table 1\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 2\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 3\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6617?source=related_link\">",
"      Coronary artery bypass grafting in patients with cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/58/33706?source=related_link\">",
"      Medical consultation for patients with hip fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34361?source=related_link\">",
"      Screening for asymptomatic carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41910?source=related_link\">",
"      Thymectomy for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_9_10395="Sleep disorders and driving";
var content_f10_9_10395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient information - Sleep disorders and automobile driving",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        You have been",
"diagnosed with sleep apnea or another sleep disorder which may",
"adversely affect your driving. People with sleep apnea or other sleep",
"disorders often have a three-fold increased rate of automobile crashes",
"or other accidents. These accidents may cause serious injury or death",
"to yourself or others.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you have had an automobile crash or frequent near crashes due to sleepiness or inattention, you should stop driving  and/or operating dangerous machinery until your sleep disorder has been treated and you no longer",
"become sleepy or inattentive while driving. It is your responsibility",
"not to drive if you are sleepy or inattentive while driving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Until your",
"treatment has begun, have your spouse or friends drive for you. If you",
"must drive, limit your driving to essential trips. You should not drive",
"for more than 20 minutes at a time, and you should not drive at night.",
"If you have further concerns about your driving, talk to your doctor.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10395=[""].join("\n");
var outline_f10_9_10395=null;
var title_f10_9_10396="Infections causing liver granulomas";
var content_f10_9_10396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infections causing granulomatous hepatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lepromatous leprosy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BCG infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listeriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melioidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersiniosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psittacosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipple disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catch scratch fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EBV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A, B and C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioidomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral larva migrans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral leishmaniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rickettsial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii (Q fever)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bontonneuse fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Spirochetal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary syphilis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10396=[""].join("\n");
var outline_f10_9_10396=null;
var title_f10_9_10397="Amyloid precursor proteins II";
var content_f10_9_10397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protein precursor of amyloid deposits-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Protein class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precursor protein (abbreviation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amyloid type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transport protein",
"       </td>",
"       <td>",
"        Transthyretin (TTR; prealbumin)",
"       </td>",
"       <td>",
"        ATTR",
"       </td>",
"       <td>",
"        Hereditary neuropathic and/or cardiopathic amyloids; vitreous amyloidosis; leptomeningeal or renal amyloid in some kindreds; senile systemic amyloidosis",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Cerebrovascular/ neurdegeneration",
"       </td>",
"       <td>",
"        Amyloid precursor protein (APP)",
"       </td>",
"       <td>",
"        ABeta",
"       </td>",
"       <td>",
"        Hereditary and sporadic Alzheimer disease; congophilic cerebral angiopathy",
"        <sup>",
"         [2,3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prion protein (PRP)",
"       </td>",
"       <td>",
"        APrPsc",
"       </td>",
"       <td>",
"        Hereditary and sporadic spongiform encephalopathies",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRI gene product",
"       </td>",
"       <td>",
"        ABri/ADan",
"       </td>",
"       <td>",
"        Hereditary dementias (British and Danish types)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystatin C (Cys - C)",
"       </td>",
"       <td>",
"        ACys",
"       </td>",
"       <td>",
"        Hereditary cerebrovascular hemorrhage with amyloidosis (Icelandic type)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Coagulation protein",
"       </td>",
"       <td>",
"        Fibrinogen alpha chain",
"       </td>",
"       <td>",
"        AFib",
"       </td>",
"       <td>",
"        Hereditary nephropathic amyloidosis",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Enzyme",
"       </td>",
"       <td>",
"        Lysozome",
"       </td>",
"       <td>",
"        ALys",
"       </td>",
"       <td>",
"        Hereditary nephropathic amyloidosis; may have marked hepatic, splenic and gastrointestinal amyloid deposits",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Other",
"       </td>",
"       <td>",
"        Keratoepithelin",
"       </td>",
"       <td>",
"        AKer",
"       </td>",
"       <td>",
"        Various familial corneal dystrophies",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactoferrin",
"       </td>",
"       <td>",
"        ALac",
"       </td>",
"       <td>",
"        Corneal amyloidosis associated with trichiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Odontogenic ameloblast-associated protein",
"       </td>",
"       <td>",
"        AOaap",
"       </td>",
"       <td>",
"        Calcifying epithelial odontogenic tumors (CEOTs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semenogelin 1",
"       </td>",
"       <td>",
"        ASem1",
"       </td>",
"       <td>",
"        Senile seminal vesicle amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactadherin",
"       </td>",
"       <td>",
"        AMed",
"       </td>",
"       <td>",
"        Senile aortic amyloid; media deposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocyte chemotactic factor 2",
"       </td>",
"       <td>",
"        ALect2",
"       </td>",
"       <td>",
"        Amyloid nephropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Connors LH, Lom A, Prokaeva T, et al. Amyloid 2003; 10:160 (TTR variants updated at file://medicine.bu.edu/amyloid/Amyloidl.htm).",
"      </li>",
"      <li>",
"       Selkoe DJ. Physiol Revs 2001; 81:741.",
"      </li>",
"      <li>",
"       Revesz T, Ghiso J, Lashley T, et al. J Neuropathol Exp Neurol 2003; 62:885.",
"      </li>",
"      <li>",
"       Prusiner SB. N Engl J Med 2001; 344:1516.",
"      </li>",
"      <li>",
"       Vidal R, Frangione B, Rostagno A, et al. Nature 1999; 399:776 and Gibson G, Gunasekera N, Lee M, et al. J Neurochem 2004; 88:281.",
"      </li>",
"      <li>",
"       Olafsson I, Grubb A. Amyloid 2000; 7:70.",
"      </li>",
"      <li>",
"       Hawkins PN. J Nephrol 2003; 16:443.",
"      </li>",
"      <li>",
"       Klintworth GK. Front Biosci 2003; 8:d687.",
"      </li>",
"      <li>",
"       Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid 2010; 17:101.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10397=[""].join("\n");
var outline_f10_9_10397=null;
var title_f10_9_10398="C reactive protein and serum amyloid A predict risk after MI";
var content_f10_9_10398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C reactive protein and serum amyloid A predict risk after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 467px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the CARE trial of 782 patients with a recent myocardial infarction, patients with serum concentrations of C-reactive protein or amyloid A in the highest quintile had a significantly greater risk for a recurrent fatal or nonfatal cardiac event compared to those with values in the lowest quintile.",
"    <div class=\"footnotes\">",
"     *p = 0.02.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators, Circulation 1998; 98:839.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10398=[""].join("\n");
var outline_f10_9_10398=null;
var title_f10_9_10399="Protein filtration in FGS";
var content_f10_9_10399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of proteinuria in FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dextran sieving profiles in patients with heavy proteinuria and the nephrotic syndrome due to focal glomerulosclerosis (FGS). A fractional dextran clearance of 1 represents complete filtration. Patients with FGS have decreased clearance of smaller dextrans but increased clearance of dextrans with a radius above 52 &Aring;, suggesting an increased number of larger pores.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Guasch, A, Hashimoto, H, Sibley, RK, et al, Am J Physiol 1991; 260:F728.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_9_10399=[""].join("\n");
var outline_f10_9_10399=null;
